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Epigenetic dysregulation, including aberrant DNA hypermethylation and histone 
deacetylation, and associated silencing of tumor suppressor genes, is critically involved 
in the development of non-small cell lung cancer (NSCLC). Targeting key regulators of 
these processes, DNA methyltransferases and histone deacetylases, can promote re-
expression of silenced genes, can produce major clinical responses, and may alter 
responsiveness to subsequent chemotherapy. Still, the mechanisms responsible for 
clinical efficacy remain controversial.  
To characterize the effects of azacitidine (Aza) and entinostat in preclinical 
models of NSCLC, we treated cell lines and assessed cytotoxicity and potential synergy 
at the end of treatment, sustained effects on proliferation, cell cycle progression, and 
colony formation days later, and effects on tumorigenic potential of xenografts initiated 
one week after treatment. We also assessed the effects of epigenetic therapy on 
chemosensitivity of cell lines in viability and colony formation assays. Furthermore, we 
examined response of cell line and patient derived xenografts to chemotherapy following 
epigenetic therapy.  
Following Aza treatment, proliferation and colony formation were inhibited in 
H358, H460, and H2170, while proliferation was less affected in H838 and H1299. 
Tumorigenicity of H358 and H1299 xenografts was also impaired. In cell viability 
assays, Aza and entinostat were generally not synergistic, or in H1299 cells, were 
antagonistic. However, the combination of Aza and entinostat at non-toxic doses 
significantly impaired tumorigenicity of H1299 xenografts compared to either agent 
alone. To a lesser degree, combinatorial benefit was observed in H460 xenografts, and in 
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H358 xenografts at higher dose entinostat. Pretreatment with epigenetic therapy did not 
alter chemosensitivity of H358, H838, H1299, or A549 in vitro, but sensitized A549 
xenografts and worsened response of H460 xenografts to irinotecan therapy in vivo. 
Combination epigenetic therapy in vivo also improved sensitivity of LX7 to repeat 
treatment with irinotecan following tumor regrowth.  
These results indicate that epigenetic therapy can produce durable anti-tumor 
effects in NSCLC at relatively non-cytotoxic doses, and suggest these effects are, at least 
in part, mediated through epigenetic mechanisms. In addition, our data demonstrating 
sensitization of select xenografts to irinotecan provide preclinical support for clinical 
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1. Lung cancer background and significance 
Lung cancer remains one of the most commonly diagnosed cancers worldwide, 
and the leading cause of cancer related death [1]. More than 228,000 new cases are 
expected in 2013 in the United States alone [2]. Approximately 80% of cases are non-
small cell lung cancer (NSCLC), comprised of several histological subtypes, 
predominantly adenocarcinoma (AdC) and squamous cell carcinoma (SqCC), and to a 
lesser extent, large cell carcinoma (LCC). In the past decade, identification of EGFR 
mutations and ALK fusions has led to advances in the treatment of NSCLC, particularly 
AdC, through the use of targeted therapies [3-5]. While other driver mutations may also 
represent viable therapeutic targets, they occur at low frequency in AdC, with  nearly half 
of cases still lacking a defined driver mutation, and have been less well defined in SqCC 
[6]. As a result, therapeutic options are limited for many patients. In addition, acquired 
resistance to existing targeted agents and disease recurrence present further challenges, 
and highlight the need for alternative treatment strategies [7-9].  
One such strategy of interest involves pharmacological modulation of the NSCLC 
epigenome, since, unlike genetic alterations, epigenetic modifications can be reversed 
through inhibition of mediating enzymes. This introductory chapter discusses the 
underlying epigenetic landscape and the therapeutic utility of targeting DNA 
methyltransferases (DNMTs) and histone deacetylases (HDAC) to reverse aberrant gene 




2. Overview of cancer epigenetics 
Human cancers contain widespread epigenetic abnormalities, including global 
DNA hypomethylation, region-specific DNA hypermethylation, global histone 
hypoacetylation, and other aberrant histone modification patterns, that alter gene 
expression and disrupt normal cell behavior [10-12]. The first of these to be described 
was global hypomethylation, which is known to cause activation of repetitive elements, 
genomic instability, and expression of oncogenes, all of which contribute to 
carcinogenesis [13-15]. Loss of both histone H4 lysine 16 acetylation (H4K16ac) and 
lysine 20 trimethylation (H4K20me3) appears to be another hallmark of early epigenetic 
dysregulation in cancer, and is associated with hypomethylated repetitive DNA regions 
[16]. In the last few years, emerging data has suggested several large scale epigenetic 
alterations in cancer, that have as of yet not been fully characterized. It appears that 
differentiation-specific H3K9me2 across large chromatin regions is lost in many cancer 
cells. These regions are characterized by a relatively low density of genes, which are 
generally CpG-poor. It has been suggested that these alterations may contribute to 
phenotypic plasticity in cancer [17]. DNA methylation occurs primarily (but not 
exclusively) at the cytosine residue of CpG dinucleotides, which are unevenly distributed 
in the genome, clustering in “CpG islands” often located in the vicinity of gene promoters 
and other regulatory elements, flanked by so-called “shores.”  Studies in several tumor 
types provide evidence that a significant portion of differential methylation in cancer 
occurs outside of CpG islands, in conserved CpG island shore regions and in large blocks 
of general hypomethylation. Methylation across the cancer genome is quite variable, and 
may contribute to tumor heterogeneity [18, 19].  
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The most extensively studied epigenetic abnormality in cancer is 
hypermethylation of CpG island promoter regions and associated transcriptional 
repression of genes. It is well established that aberrant methylation, which can affect 
hundreds of genes in a given cancer, including numerous tumor suppressor genes (TSGs), 
plays a critical role in carcinogenesis. Hypermethylated and transcriptionally silenced 
genes are associated with compact heterochromatin characterized by loss of active 
H3K9ac and H3K4me3 and gain of repressive H3K27me3 and H3K9me2/me3 histone 
marks [11, 12]. While this has been known for some time, only in recent years have we 
begun to better understand the complexity of de novo methylation and gene silencing in 
cancer. In stem cells, genes involved in regulation of development and differentiation 
normally exhibit a poised transcriptional state in which surrounding chromatin is 
maintained in a bivalent state manifest by coexistence of both repressive H3K27me3 and 
activating H3K4me3 marks. In cancer cells, these genes often lose this plasticity and 
become more stably repressed by addition of repressive H3K9me2 and H3K9me3 marks 
and DNA promoter region methylation [20-25]. While it has become evident that 
aberrant gene silencing in cancer is a complex process involving histone methylation and 
multiple mediating enzymes [26], it remains clear that removal of histone acetylation by 
HDAC enzymes plays a critical role in transcriptional repression of TSGs, particularly 
considering laboratory findings that histone deacetylation and methylation can trigger 
chromatin inactivation and gene silencing prior to DNA methylation [27-29]. A recent 
report by Coolen et al. further highlights the important of HDACs in gene silencing. The 
authors identified, in prostate cancer, regions of long-range epigenetic silencing (LRES), 
approximately 2Mb in size, that typically contain silenced tumor suppressor and miRNA 
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genes. These regions contained distinct subdomains of different silencing marks, 
including DNA methylation, H3K9me2, and H3K27me3, but the common feature  
through LRES was loss of H3K9ac, emphasizing the importance of deacetylation in 
establishing and maintaining these silenced regions [30].  
 
3. Epigenetic dysregulation in NSCLC 
3.1 Aberrant DNA hypermethylation and gene silencing 
Loss of gene function, whether by genetic alteration or epigenetic silencing, 
results in disruption of a variety of critical cellular processes, providing the framework 
for oncogenic transformation. In NSCLC, focal hypermethylation and silencing of TSGs 
affects numerous key biological processes, including cell cycle regulation (p16), DNA 
repair (MGMT), apoptosis (DAPK), regulation of RAS (RASSF1A) and Wnt (APC) 
signaling, and suppression of invasion (CDH13, TIMP3), among many others [11, 31-
33]. Indeed, TSG silencing contributes to virtually all of the hallmarks of cancer [34]. 
Candidate gene based studies have demonstrated that hypermethylation of TSGs 
including p16, MGMT, RASSF1A, and APC, often occurs early during neoplasia and 
increases during progression to carcinoma, pointing to the involvement of these events in 
both initiation and progression of disease [33, 35-37]. Clinically, candidate gene 
approaches have linked methylation and silencing of TSGs, including genes methylated 
during the earliest stages of disease, to recurrence after surgical resection. For example, 
one study found that methylation of p16 and concomitant loss of p16 protein expression 
correlated with shorter survival after resection [38]. Another study noted that concurrent 
methylation of p16 and CDH13, or with APC or RASSF1A, is strongly associated with 
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recurrence following resection of stage I NSCLC [39]. It has been suggested that early 
silencing events may facilitate abnormal expansion of precancerous cells and allow for 
accumulation of genetic and epigenetic abnormalities needed to drive tumorigenesis [12, 
40]. The existence of abnormal clones harboring early TSG silencing in adjacent, 
nonresected tissue may contribute to increased risk of recurrence.  
As new approaches and technologies have been developed in recent years, a shift 
from candidate gene based approaches to genome-wide methylation profiling has 
occurred, allowing for more comprehensive interrogation of DNA methylation patterns in 
NSCLC. Using the Illumina Infinium HumanMethylation27K array platform, Selamat et 
al. identified more than 700 common differentially methylated genes among 59 AdC and 
matched normal tissues. Hierarchical clustering revealed the existence of two distinct 
subgroups within the AdC tumors, with one subgroup exhibiting greater DNA 
methylation and a higher likelihood of concomitant mutation in Kras. Differential 
methylation of these genes correlated with altered expression of 221 genes involved in 
pathways including cell cycle control, differentiation, epithelial-to-mesenchymal 
transition, and proliferation. Roughly 75% of these altered genes were frequently 
hypermethylated and silenced in tumors [41].  
Shinjo et al. recently classified AdC tumors based on the presence of a CpG 
island methylator phenotype (CIMP), originally defined in colon cancer following 
observation of tumors with consistent, dense, cancer-specific hypermethylation of 
multiple loci [42]. Using methylated CpG island amplification microarray (MCAM) 
analysis, the authors identified a novel six gene CIMP marker panel. The authors then 
assessed methylation status of their CIMP markers in 85 AdC data sets from The Cancer 
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Genome Atlas (TCGA) database, which were generated using the Infinium 
HumanMethylation27K array platform. Interestingly, while this array contained promoter 
region probes for only three CIMP markers (ACAN, CCNA1 and GFRA1), methylation of 
one or two markers correlated with increased overall methylation of the most variable 
probes in the TCGA data sets [43]. However, the value of these CIMP markers as 
predictors of overall methylation in AdC is currently unclear. 
A recent study by Lockwood et al. incorporated genome-wide methylation, 
expression, and copy number analysis to compare AdC and SqCC primary tumors. 
Subtype-specific gene expression patterns resulting from both copy number disparity and 
differential methylation were discovered, and correlated with disruption of distinct 
pathways. SqCC tumors exhibited altered expression of histone modifying enzymes as a 
result of copy number alteration and greater overall hypomethylation. The authors noted 
several genes, including the tumor suppressor FHIT, silenced in SqCC due to both copy 
number loss and hypermethylation [44].  
Taken together, these data both add to the wealth of existing evidence that 
aberrant DNA hypermethylation is critically involved in malignancy, and highlight that, 
like genetic alterations, epigenetic abnormalities are highly variable in NSCLC, both 
within and across histological subtypes. While tumor heterogeneity presents major 
challenges for the use of targeted agents, due to the potential for variable compensatory 
mechanisms and modes of resistance, modulation of epigenetic abnormalities, such as 
aberrant hypermethylation, may provide advantages through the ability to broadly 




3.2 DNA methyltransferases  
Three catalytically active DNA methyltransferases, DNMT1, DNMT3a, and 
DNMT3b, mediate the methylation of cytosine residues in CG dinucleotides in 
mammalian cells. DNMT1 is primarily involved in maintenance of methylation following 
replication and DNA repair. DNMT3a and DNMT3b facilitate de novo methylation, and 
appear to have a maintenance role as well [45, 46]. In cancer cells, hypermethylation of 
genes may be particularly dependent on both DNMT1 and DNMT3b [47, 48], and 
DNMT1 may have a cancer-specific role in de novo CpG island hypermethylation [49]. 
Dysregulated expression of these enzymes has been implicated as a cause of 
aberrant methylation in cancer. All three DNMTs are overexpressed in NSCLC, and 
DNMT1 overexpression in particular has been correlated with poor prognosis [50-53]. 
Dysregulation of expression may occur through various mechanisms. One study showed 
that loss of p53 function accompanied by overexpression of Sp1, a known transcriptional 
activator of DNMT1, is associated with DNMT1 overexpression in NSCLC tumors [52]. 
Another demonstrated that MDM2 overexpression and concurrent low Rb expression 
correlate with upregulated DNMT3a [53]. Both studies associated elevated DNMT levels 
with increased methylation of candidate TSGs. Several microRNAs are also known to 
modulate DNMT expression [54]. For example, miR-29 family members downregulate 
DNMT3a and DNMT3b directly, and DNMT1 indirectly, through interaction with the 3’ 
untranslated region and Sp1, respectively [55, 56]. Decreased miR-29 has been associated 
with increased DNMT3a and DNMT3b expression in NSCLC [55]. Loss of temporal 
control of DNMT1 protein stability has been observed in breast cancer, resulting in 
elevated protein levels independent of transcript upregulation [57]. This impaired 
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proteasomal degradation of DNMT1 results, at least in part, from association with the 
chaperone Hsp90, maintained in a deacetylated state by HDAC1 [58]. The histone 
demethylase LSD1 has also been reported to stabilize DNMT1 by removal of SET7/9 
mediated lysine methylation [59]. Overexpression of HDAC1 and LSD1, which occurs in 
NSCLC and has been associated with poor prognosis [60-62], may also contribute to the 
dysregulation of DNMT1 by promoting protein stability. In addition, variant forms of 
DNMT3b, resulting from alternative promoters and alternative transcript splicing, have 
been identified and are commonly expressed in NSCLC but not in normal lung. 
Expression of these variants has been associated with TSG methylation and poor clinical 
outcome [63, 64].  
While overexpression has implicated all three DNMTs as contributors to 
oncogenesis in NSCLC, the actual role of DNMT3a is less clear. A recent study found 
loss of DNMT3a expression in 13/28 NSCLC patient tumors, resulting from loss of 
heterozygosity (LOH) in five cases, and unknown mechanisms in the remaining eight. In 
addition, three tumors harbored previously unreported mutations in DNMT3a, however 
none were associated with loss of expression [65]. While the consequences of DNMT3a 
loss in NSCLC are not yet understood, recent preclinical evidence suggests a paradoxical 
tumor suppressor role for this enzyme. Work using a conditional Kras mutant AdC 
mouse model demonstrated that loss of DNMT3a was associated with altered expression 
of nearly 2000 genes, decreased methylation across the majority of differentially 
methylated regions, including gene bodies, and enhanced proliferation and progression of 
more poorly differentiated tumors. Mechanistic studies were lacking, but the authors 
speculated that DNMT3a-mediated gene body methylation may promote expression of 
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differentiation genes, and that DNMT3a loss impairs differentiation of tumor initiating 
cells [66]. This model is supported by reports that differentiation of certain cell types 
requires DNMT3a, both for gene body methylation and associated expression of 
differentiation genes, as well as silencing of genes critically involved in stem cell 
maintenance [67, 68]. However, this appears contrary to the findings that DNMT3a-
mediated gene body non-CpG methylation, which is present in embryonic stem cells, is 
lost in differentiated fibroblasts, with concurrent reduction in DNMT3a expression [69]. 
While the exact functions may be tissue and context dependent, these recent findings 
have important implications, given the occurrence of DNMT3a mutations and 
dysregulated expression in cancer. Since strategies aimed at reversal of hypermethylation 
and gene silencing utilize agents that target all enzymatically active DNMTs, it is 
important to further define the role of DNMT3a in NSCLC. 
 
3.3 Histone deacetylases 
Chromatin structure is governed by the dynamic interplay of a multitude of 
histone modifying enzymes and the post translational modifications they mediate. 
Histone deacetylases (HDACs) catalyze the removal of acetyl groups from lysine 
residues on histone tails to induce chromatin compaction and transcriptional repression. 
There are 18 identified human HDAC isoforms, separated into four classes (Table 1). 
Classes I, II, and IV contain metalloenzymes that require Zn
2+
 for catalytic activity, 
whereas class III, or sirtuins, use an NAD
+ 
dependent mechanism. Discussion here will 
be restricted to zinc metalloenzymes, as these are the targets of the majority of 
investigational and all FDA approved HDAC inhibitors (HDIs). Class I HDACs (1, 2, 3, 
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8) are ubiquitously expressed in normal tissues and preferentially located in the nucleus, 
whereas class II (4, 5, 6, 7, 9, 10) and IV HDACs (11) have tissue-specific expression 
patterns, and move between the nucleus and cytoplasm, or in the case of HDAC6 and 
HDAC10, are preferentially found in the cytoplasm [70].  
 
Table 1. Histone deacetylases (HDAC) 







Primarily in nucleus; HDAC3 and 







 Nucleus and cytoplasm Tissue specific 
IIb HDAC6, HDAC10 Zn
2+
 
Primarily in cytoplasm; HDAC10 
also in nucleus 
Tissue specific 





 Nucleus and cytoplasm Tissue specific 
 
Class I enzymes are generally involved in proliferation and survival, while class II 
HDACs have been implicated in differentiation and development [70]. As reviewed 
elsewhere, HDACs alter the activity of many non-histone targets through deacetylation 
[70, 71]. One example, previously mentioned, is the chaperone Hsp90, whose 
deacetylation by HDAC1 or HDAC6 allows it to interact with DNMT1, which prevents 
proteasomal degradation of the methyltransferase [58, 71].  
HDAC expression is commonly altered in cancer, and overexpression has been 
noted in multiple cancer types [70, 71]. As mentioned previously, HDAC1 is highly 
overexpressed in NSCLC [60, 61]. In addition, one study found upregulation of HDAC3 
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protein in 92% of squamous cell tumors [72]. Interestingly, it has been reported that 
several class II enzymes, particularly HDAC5 and HDAC10, are downregulated in 
NSCLC, and downregulation of either is a negative prognostic factor [73]. In addition to 
expression alterations, HDAC activity may be dysregulated due to existing aberrant 
methylation. HDACs can be recruited to sites of hypermethylation through interaction 
with methyl-binding proteins, DNMT, and co-repressors such as mSin3A [10, 12], 
resulting in the targeting of HDACs to inappropriate chromatin sites, and aberrant 
patterns of deacetylation. Finally, HDACs, through their integral role in heterochromatin 
formation, may indirectly contribute to increased genetic variation in cancer, as regions 
of repressive chromatin have been associated with increased mutation rates in lung, 
colon, melanoma, and leukemia cells [74]. 
 
4. Targeting the NSCLC epigenome 
4.1 DNMT inhibitors  
The significance of aberrant hypermethylation cancer in general, along with the 
frequent dysregulation of DNMTs levels in lung cancer, certainly makes these enzymes 
attractive drug targets. Ironically, agents that target DNMTs have existed for more than 
40 years, long before hypermethylation in cancer was discovered. It was not until 1980 
that Taylor and Jones discovered that azacitidine (5-azacytidine, Vidaza®) and decitabine 
(5-aza-2’-deoxycytidine, Dacogen®), which were originally developed as cytotoxic 
drugs, could induce loss of DNA methylation and differentiation of cells [75]. The 
generally accepted mechanism involves incorporation of these azanucleosides into DNA, 
followed by the covalent trapping of DNMTs to the DNA, and subsequent proteasomal 
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degradation of the enzymes [76-80]. DNA damage and impaired DNA synthesis resulting 
from these DNA-DNMT adducts is likely responsible for much of the cytotoxicity 
induced by these agents, particularly at higher doses [77, 78, 80-83]. While decitabine is 
specific to DNA, azacitidine is also incorporated into RNA, which may explain 
differential effects of these agents with regard to toxicity and gene reactivation [78, 84, 
85].  
The hypomethylating effects of these agents are best realized at doses below the 
cytotoxic range [75], and it was not until lower dose, prolonged treatment regimens were 
employed that this was appreciated clinically. As a result, testing of low dose regimens 
resulted in FDA approval of both agents in the mid-2000s for treatment of 
myelodysplasia (MDS), and of decitabine for acute myelogenous leukemia (AML) [80]. 
The value of lowered doses has been further defined in the laboratory. Tsai et al. 
demonstrated that relatively low doses of demethylating agents could impair the 
clonogenic and tumorigenic capacity of leukemia and breast cancer cell lines, and induce 
reactivation of tumor suppressor genes to restore critical regulatory pathways. In 
addition, the authors showed in vivo that lower doses of azacitidine were as or more 
effective than higher doses at inhibiting growth of breast cancer xenografts in mouse 
models [86]. 
Early trials using demethylating agents in advanced lung cancer showed limited 
success. In a pilot phase I/II study, three of 15 stage IV NSCLC patients treated with 
high-dose decitabine (200-660mg/m
2
) demonstrated evidence of prolonged survival, with 
one individual surviving a surprising 81 months. However, only six patients received 
more than one decitabine infusion because 5-7 week intervals were needed to manage 
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hematopoietic toxicities, no doubt limiting the potential for efficacy in this trial [87]. 
Schrump et al. conducted a phase I dose escalation study of decitabine, starting at lower 
doses, in 35 patients with solid tumors, including 20 NSCLC patients. No objective 
responses were noted, and stable disease was achieved in only four patients, including 
three SqCC patients, and one patient with small cell lung cancer.   Decitabine-induced 
expression of p16, MAGE-3, or NY-ESO-1 protein (assessed by immunohistochemistry) 
was observed in approximately one-third of patients. Consistent with repeated exposure 
to decitabine, one patient with prolonged stable disease exhibited progressive increases in 
MAGE-3 and NY-ESO-1 mRNA, with markedly increased expression at six and eight 
months.  Interestingly, no patients receiving the highest dose of decitabine 
(30mg/m
2
/day) achieved stable disease [88], consistent with the suggestion from myeloid 
malignancies that lower doses are more effective [80]. While early studies like these 
caused many to believe demethylating agents were of little use in solid tumors, future 
studies employing regimens successfully used in MDS and AML may provide different 
results. 
While not as extensively studied as azacitidine and decitabine, other 
demethylating agents, such as the anti-hypertensive hydralazine and the cytidine analog 
zebularine, have been tested in the clinic, but with limited success. One promising agent 
is SGI-110, a dinucleoside containing decitabine with improved stability [89] that is 
currently being tested in a phase I/II trial in MDS and AML. It remains to be seen 




4.2 HDAC inhibitors 
Since the discovery that trichostastin A (TSA) inhibited HDACs and caused 
differentiation and cell cycle arrest in mammalian cells [90], numerous HDAC inhibitors 
(HDIs) have been synthesized and studied for their potential as anti-cancer agents [71, 
91]. To date, only two have been FDA approved: vorinostat (SAHA, Zolinza®) and 
romidepsin (depsipeptide, Istodax®). Both drugs are approved for use in cutaneous T cell 
lymphoma, while romidepsin is also approved for treatment of peripheral T cell 
lymphoma. Current HDIs encompass several chemical classes, and differ in the HDAC 
isoforms they target (Table 2) [71, 91].  
 
Table 2. Common HDAC inhibitors 
Chemical Category Compound Deacetylase selectivity 
Aliphatic acid Phenylbutyrate 
Valproic Acid (VPA) 
Class I, IIa 
Class I, IIa 
Hydroxamate Trichostatin A (TSA) 
Vorinostat (SAHA, Zolinza) 
Panobinostat (LBH589) 
Belinostat (PDX101) 
Class I, II, IV 
Class I, II, IV 
Class I, II, IV 
Class I, II, IV 




Cyclic tetrapeptide Romidepsin (Depsipeptide, Istodax) Class I 
 
It is currently unknown whether increased selectively of HDIs for specific HDAC 
isoforms limits toxicities or increases anti-tumor efficacy. Targeting nuclear specific 
15 
 
class I HDACs may have a more specific effect on histone acetylation with fewer effects 
on “off-target” non-histone cytoplasmic proteins. The relative benefits of narrow vs. 
broad targeting may be tissue and context dependent, influenced by the roles of 
epigenetic modulation and of the non-histone HDAC target proteins in a given cancer. 
One study defined a nine-gene panel in NSCLC cells predictive of sensitivity to TSA and 
vorinostat, but did not explore whether this panel would be predictive of benefit from a 
class I-specific HDI [92].   
A wide array of phenotypic effects caused by HDI treatment of cancer cells has 
been documented [70, 91]. HDIs cause G1-phase cell cycle arrest through activation of 
p21 and repression of cyclin expression. These agents have been shown to activate both 
the extrinsic and intrinsic apoptotic pathways by altering expression of death receptors 
and ligands, as well as the balance of key intracellular pro- and anti-apoptotic regulators 
[70, 91]. Preclinical studies in NSCLC cell lines have demonstrated that induction of 
apoptosis in response to HDIs also involves downregulation of checkpoint kinase 1 
(Chk1) [93]. HDIs induce generation of reactive oxygen species (ROS) and cause DNA 
damage, and can downregulate expression of DNA repair genes. In addition, HDIs have 
been shown to downregulate pro-angiogenic and matrix remodeling genes, suggesting 
that these agents may be useful in suppressing angiogenesis and metastasis. HDIs also 
impair glucose metabolism through targeting of the glucose transporter 1 and hexokinase 
1 [70]. Finally, HDIs may modulate immunogenicity of cancer cells through upregulation 
of molecules involved in T-cell and NK cell activation, such as MHC class I and II, 
CD80/CD86, and MICA/MICB [70, 91]. 
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Due to the small number of NSCLC patients in many of the trials, clinical data for 
HDI monotherapy in NSCLC is limited. In general, the results in advanced, solid tumors 
have been disappointing. While well tolerated, these agents typically produce only stable 
disease as the best response, with rates varying from 15-75% depending on the clinical 
context and the HDI tested [94-102]. In a small phase II study of vorinostat in patients 
with relapsed NSCLC, stable disease ranging from 1.4-19.4 months was achieved in 8/14 
patients [101]. In another phase II study of vorinostat, 4 of 8 evaluable NSCLC patients 
achieved stable disease lasting 44-98 days [100]. In a phase II trial of romidepsin, disease 
stabilization was achieved in 5/15 evaluable NSCLC patients, however this lasted more 
than four months in only three patients. Interestingly, correlative studies demonstrated 
that romidepsin induced p21 expression, H4 acetylation, and a general shift toward 
expression patterns in adjacent normal bronchial epithelial cells, demonstrating 
epigenetic modulation in patients [98]. While the available data does indicate that current 
HDIs alone are unlikely to provide substantial benefit to unselected NSCLC patients, 
they may have utility in combination with other agents. Vorinostat has been shown to 
improve response rate to first-line therapy with carboplatinum and paclitaxel in advanced 
NSCLC, although no survival benefit was seen [103]. Addition of entinostat to erlotinib 
provided no overall benefit relative to erlotinib alone in advanced, chemo-refractory 
NSCLC, but appeared to improve survival in a subset of patients with high tumor E-




4.3 Combination epigenetic therapy 
Elucidation of the involvement of HDACs in TSG silencing in cancer led to the 
hypothesis that combined DNMT and HDAC inhibition might result in enhanced or 
sustained TSG reactivation (Figure 1).  
 
 
Figure 1.  Epigenetic changes in cancer and combinatorial epigenetic therapy.   
Upper panel shows a typical tumor suppressor gene in a normal cellular context, with increased 
density of CpG dinucleotides (defining a CpG island) surrounding the transcriptional start site 
indicated in the blue arrow. Chromatin in the region of an actively transcribed gene is typically in 
a relatively open configuration, as shown, with space between nucleosomes allowing access by 
transcription factors. Lower panel shows typical changes associated with epigenetic silencing of 
a tumor suppressor gene in cancer. DNA methylation is markedly increased within the CpG 
islands, and chromatin has assumed a closed configuration with tightly packed nucleosomes. 
Combined epigenetic therapy attempts to reverse these changes: azacitidine results in 
demethylation of the DNA, and entinostat inhibits histone deacetylase, shifting the chromatin to a 
18 
 
more open configuration. Targeting both of these levels of epigenetic silencing concurrently may 
lead to synergistic re-expression of tumor suppressors. 
 
This idea does have support from preclinical data. In 1999, Cameron et al. 
demonstrated that the combination of decitabine and TSA synergistically reactivated 
silenced TSGs in colon and leukemia cell lines [105]. This was a pivotal paper at the time 
because it demonstrated that the functional link between DNA methylation and histone 
deacetylation in gene silencing could be exploited pharmacologically. Shortly after, 
studies in vitro showed additive to synergistic inhibition of DNA synthesis, loss of 
clonogenicity, and induction of apoptosis in NSCLC cell lines treated with the 
combination of decitabine and an HDI (phenylbutyrate, depsipeptide, TSA) [106-108]. In 
addition, the combination of decitabine and phenylbutyrate was shown to synergistically 
inhibit development of lung lesions following exposure of mice to the carcinogen, NNK 
[108]. 
Recently, Belinsky et al. reported efficacy of combined azacitidine and entinostat 
therapy in immunocompromised rat orthotopic models of AdC. Combination therapy was 
roughly twice as effective as azacitidine alone in reducing growth of Kras mutant Calu-6 
tumors, and also markedly reduced growth of two additional Kras (A549) and EGFR 
(H1975) mutant tumors. Both therapies induced demethylation and reexpression of 
numerous genes, including the tumor suppressors p16 and p21, pro-apoptotic genes, and 
Polycomb (PRC2) target genes, and downregulated expression of the histone 
methyltransferase and PRC2 component, EZH2. A clear trend toward greater effect on 
gene expression was seen with combination over azacitidine alone [109]. In addition to 
showing efficacy against NSCLC models, these studies provide mechanistic insights into 
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the anti-tumor effects of epigenetic therapy. Not surprisingly, these involved reactivation 
of key regulators of apoptosis and cell cycle progression, including TSGs commonly 
hypermethylated in NSCLC.  
Despite preclinical evidence supporting the utility of combined epigenetic therapy 
and successful use of combination regimens in the treatment of AML and MDS [110, 
111], initial trial results in solid tumors were underwhelming. The combination of 
azacitidine and phenylbutyrate lacked evident clinical benefit [112], whereas the 
combination of azacitidine and valproic acid yielded only stable disease in 14/55 solid 
tumor patients [113]. However, a very recent phase I/II trial of the combination of 
azacitidine and entinostat in advanced, chemo-refractory NSCLC patients has renewed 
substantial interest in this therapeutic strategy. The patient population enrolled in this trial 
had a median of three prior therapies, and achieved a 6.4 month median survival, similar 
to that of erlotinib in second and third line therapy (the only FDA approved therapy in 
this context). While only 2/34 evaluable patients had objective response (1 CR for 14 
months, 1 PR for 8 months), another 10 had disease stabilization for at least 12 weeks, 
with durations of 14 and 18 months in two patients [114]. The durability of these 
responses was particularly striking. Uncovering biomarkers that predict which patients 
are likely to derive benefit is important for any therapy. Exploratory results from this 
cohort suggest that reduction in promoter methylation of  two or more of four genes 
previously associated with disease recurrence [39] in circulating tumor DNA from the 




5. Epigenetic therapy for sensitization and reversal of drug resistance 
 Another intriguing observation from this trial, which we are continuing to 
explore, was the observed responses to subsequent chemotherapy following epigenetic 
therapy in this heavily pretreated population. Several patients, including patients who 
progressed quickly on epigenetic therapy, seemed to respond surprisingly well to their 
next therapy.  Notably, two patients that received only one subsequent treatment regimen 
survived 44 and 52 months after epigenetic therapy [114]. Interestingly, the previously 
mentioned decitabine treated patient that survived 81 months had also received 
chemotherapy roughly six months after decitabine [87]. While these represent a small 
number of patients, this certainly raises the question as to whether epigenetic therapy 
reprograms cancers in a manner that increases susceptibility to later therapies.  
Epigenetic mechanisms have been previously implicated in drug resistance [115], 
providing potential mechanisms for epigenetic therapy priming subsequent response. One 
study demonstrated decitabine-induced sensitization of mismatch repair-deficient ovarian 
and colon cancer xenografts to cisplatin, carboplatin, temozolomide, and epirubicin 
following demethylation and reactivation of the DNA repair gene, hMLH1 [116]. 
Another reported that TSA treatment sensitized a cisplatin-resistant AdC cell line to 
cisplatin by restoring DAPK protein expression [117]. A particularly insightful recent 
paper described the expansion of drug tolerant clones following treatment of an EGFR 
mutant NSCLC line with an EGFR inhibitor as a result of increased expression of the 
histone demethylase, JARID1A/KDM5A, loss of H3K4me2/me3 histone marks, and 
altered IGF1-R signaling [118]. Cells with this altered chromatin were highly sensitive to 
HDI mediated DNA damage, and treatment with HDIs prevented or suppressed the drug 
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tolerant phenotype. This study directly implicated a reversible epigenetic mechanism in 
drug resistance, and demonstrated the ability to revert the phenotype through epigenetic 
modulation. Finally, Cooper et al. demonstrated that reactivation of the Wnt pathway 
antagonist  sFRP1 by the combination of decitabine and romidepsin led to synergistic 
growth inhibition and apoptosis in renal cell carcinoma and triple-negative breast cancer 
lines [119]. These data are intriguing given the direct involvement of TSG reactivation in 
response to therapy in lines that correspond to generally chemo-resistant tumor types. 
 Few trials have formally tested these concepts in solid tumors. A single-arm phase 
II study of hydralazine, a weak non-nucleoside DNMT inhibitor, in combination with 
valproic acid in patients with solid tumors demonstrated responses (4 PR, 8 SD)  to 
chemotherapy on which patients were previously progressing [120]. Recently, two trials 
have demonstrated the ability of a demethylating agent to sensitize platinum-resistant 
ovarian cancers to carboplatin. Response rates following azacitidine and decitabine 
pretreatment were 22% and 35%, respectively [121, 122]. The potential for epigenetic-
mediated reversal of resistance to chemotherapy and targeted therapy is exciting given 
the limited treatment options available for advanced NSCLC, and warrants further testing 
in both laboratory and clinical settings. 
 
6. Discussion 
NSCLC is a disease characterized by both genetic and epigenetic heterogeneity, 
making traditional histological subtype classifications insufficient for informing 
treatment decisions. Classification based on mutational profiling of oncogenic drivers has 
led to substantial advances in the treatment of a subset of patients with advanced NSCLC.  
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A large fraction of patients, however, have cancers lacking any of the known clinically 
relevant driver mutations.  Cancer-specific epigenetic dysregulation of gene expression 
may be as important as mutation in driving oncogenesis, and represents an alternative 
mechanism for modulating key proliferative and survival pathways. The frequent 
epigenetic silencing of TSG in NSCLC provides interesting “targets” for epigenetic based 
therapies, and preclinical data continues to support their potential therapeutic value. 
Epigenetic regulation of gene expression is multifaceted, involving a host of 
enzymes modifying both DNA and DNA-associated protein complexes.  Many of the 
critical epigenetic modifications have been defined, and several of the epigenetic 
modifiers that appear to be dysregulated in cancer can now be inhibited with a variety of 
targeted agents in preclinical and clinical development. Rational use of these agents has 
made advances from the early days of high dose administration associated with 
substantial toxicity and minimal efficacy. Initial studies of single agent epigenetically 
targeted drugs, including the DNMT inhibitors azacitidine and decitabine, as well as a 
variety of HDAC inhibitors, have shown minimal clinical activity in lung cancer patients. 
However, a recent study exploring the combination of the DNMT inhibitor azacitidine 
with the HDAC inhibitor entinostat, concomitantly targeting two critical facets of 
epigenetic gene silencing, does appear to have interesting clinical activity.  This activity 
includes objective responses to the therapy itself as well as a possible priming effect, 
manifest as apparent improvement in tumor responses to subsequent therapies.  Important 
measures of clinical outcome, including overall survival, appear to correlate with target 
gene demethylation detectable in circulating DNA in patients treated with this therapy.   
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Still, the clinical utility of epigenetic therapy in NSCLC is only starting to be 
explored, and many unanswered questions remain. While mounting preclinical evidence 
suggests that TSG reactivation and associated reestablishment of critical regulatory 
mechanisms are intimately involved in the anti-tumor effects of epigenetic therapy [86, 
109], this has been difficult to convincingly demonstrate, and the underlying mechanisms 
responsible for clinical response remain controversial [80]. Initial clinical results suggest 
that select patients derive significant benefit from combination epigenetic therapy, and 
biomarker driven studies are needed to better identify these patients. The observation that 
patients who progress on epigenetic therapy may still benefit through improved 
sensitivity to subsequent therapy [114] presents an exciting avenue for future research, 
particularly when put into context with existing implications of epigenetic mechanisms in 
drug resistance [115], and the potential for epigenetic agents to reverse these mechanisms 
in model systems [116-118].  
Future studies will further explore these preliminary observations, including 
additional evaluation of predictive biomarkers, and formal testing of the priming 
hypothesis. Improvements in genome wide methylation profiling are defining a key level 
of the epigenetic landscape, and have the potential, in the future, to provide a means for 
screening patients to guide treatment decisions, much in the way that mutational 
screening has done for targeted therapies. This will require determination of specific 
profiles associated with response to given agents, but large scale efforts such as the 
TCGA may make this possible.  
Given the extensive evidence that epigenetic dysregulation is intimately involved 
with oncogenesis, targeting this epigenetic dysregulation has become a major clinical 
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focus.  There may, however, be substantial risks as well as benefits in indiscriminately 
altering the epigenetic landscape. The use of hypomethylating agents in the context of an 
already hypomethylated tumor epigenome has raised concerns that reactivation of 
silenced tumor suppressor genes may come at the cost of activating growth and invasion 
promoting genes, and increasing genomic instability [13-15, 19, 89]. The potential tumor 
suppressor role of DNMT3a also raises concerns about indiscriminate treatment with 
demethylating agents [66]. It remains to be seen whether these concerns are warranted, 
and whether epigenetic therapy will have long term benefit or long term negative 
consequences in malignant or normal tissues. The current data in NSCLC patients, 
demonstrating rare but impressively prolonged responses either to epigenetic therapy or 
to subsequent treatments, suggests that the benefits for these patients may outweigh these 
risks. Given the lack of effective treatment options for many in this patient population, 
further exploration of combinatorial epigenetic therapy is warranted. 
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II. Epigenetic therapy alters proliferative and tumorigenic potential of NSCLC 
1. Introduction 
In addition to genetic alteration, epigenetic dysregulation is a central contributor 
to carcinogenesis, and has garnered considerable attention in cancer therapeutic research. 
Aberrant DNA methylation and histone deacetylation have been shown to contribute to 
oncogenesis through the silencing of critical tumors suppressor genes [10-12, 27-29]. 
Like many cancers, NSCLC contains widespread epigenetic alterations, and tumor 
suppressor gene silencing is an early and critical event in lung cancer development [31-
33, 35-37]. Key regulators of these aberrant epigenetic changes include DNA 
methyltransferases (DNMTs) and histone deacetylases (HDACs), both of which can be 
targeted pharmacologically.  
The nucleoside analogs azacitidine (Aza) and decitabine (DAC) have been 
extensively studied and shown to covalently inhibit DNMTs and induce their 
degradation, resulting in loss of DNA methylation [75-81]. DNMT inhibitors were 
previously explored at or near maximally tolerated doses, levels at which these agents are 
cytotoxic but have suboptimal effects on DNA methylation. Use of these agents at 
substantially lower doses has resulted in the successful treatment of hematologic 
malignancies, including acute myelogenous leukemia (AML) and myelodysplasia 
(MDS), in select patients [80].  
The combination of demethylating agents and HDAC inhibitors (HDIs) has 
shown considerable promise, both in the laboratory and the clinic. Preclinical studies 
have demonstrated additive to synergistic effects on re-expression of silenced tumor 
suppressor genes, induction of apoptosis, inhibition of clonogenicity, and reduction in 
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tumor burden in various models [105-109]. Combinatorial epigenetic therapy has 
previously been used with success in the treatment of AML and MDS [110, 111]. 
Recently, combining Aza with the class I specific HDI, entinostat, resulted in major 
objective responses in select patients with advanced stage NSCLC [114]. 
While this activity in advanced stage NSCLC is certainly encouraging, many 
relevant questions remain. Preclinical and clinical evidence have demonstrated that lower 
doses of demethylating agents have improved efficacy over high, cytotoxic doses in 
hematologic malignancies, and in laboratory models of breast cancer [80, 86]. While 
preclinical studies strongly suggest that the anti-cancer effects of epigenetic agents 
correlate with alterations in DNA methylation and gene expression, and the associated 
reestablishment of critical regulatory pathways [86, 109], a causal relationship has been 
difficult to demonstrate clinically, and the mechanisms responsible for clinical efficacy 
remain controversial [80, 110, 111].  
Using various models of NSCLC encompassing the three most common 
histological subtypes (adenocarcinoma, squamous cell carcinoma, and large cell 
carcinoma), we sought to evaluate whether Aza, entinostat, or combination epigenetic 
therapy alters the tumorigenic capacity of NSCLC, and whether these effects correlate 
with acute cytotoxicity. We found a lack of correlation between early cytotoxicity and a 
durable anti-cancer effect in our models, suggesting the involvement of additional 




2.1 NSCLC cell lines exhibit differential sensitivity to Aza in cell viability assays 
 Given the lessons learned in the clinical treatment of AML and MDS regarding 
the improved efficacy of lower, less toxic doses of Aza [80], we first sought to define 
doses of Aza that do not result in acute cytotoxicity in NSCLC cell lines. To this end, we 
assessed sensitivity to Aza in a panel of six NSCLC cell lines, including three 
adenocarcinoma lines (H358, H838, and A549), one squamous cell carcinoma line. Cells 
were treated every 24h for 72h with Aza from 10nM-10uM, with five replicates per dose. 
Immediately following treatment, cell viability was assessed using the CellTiter-Glo 
luminescence cell viability assay (Promega). Raw data was corrected for background 
luminescence and the x-axis was log transformed (x=log(x)). Nonlinear regression using 
the equation log inhibitor vs. response with variable slope was performed to determine 
IC50 and R
2
. Mean values with standard deviation from 2-3 independent experiments are 
displayed in table 3, and depict varying sensitivity to Aza among the cell lines tested. 
H460 was the only cell line to exhibit a sub-micromolar IC50 for 72h Aza treatment. Log 
dose response curves generated from nonlinear regression of transformed data normalized 
to untreated control cells also highlight the variable sensitivity among cell lines (Figure 
2). In addition to having the lowest IC50, H460 cells also exhibited the greatest maximal 
reduction in cell viability following Aza treatment. Generally, H358 and H1299 viability 
were unaffected by doses of near 1uM Aza and below. Interestingly, A549 cells appeared 
to increase in proliferation with increasing doses of Aza up to 1uM, prior to rapidly 
decreasing in cell viability at higher doses. This effect was extremely reproducible across 




Table 3. IC50 values for NSCLC cell lines treated with azacitidine.  
Mean IC50 and R
2
 with standard deviation calculated from two (H358, H2170) or three (H460, 
H358, H1299, A549) independent experiments, each with five replicates per dose tested, from log 
transformed data analyzed by nonlinear regression in GraphPad Prism 5. The CellTiter-Glo assay 
was used to assess cell viability following 72h treatment with Aza. A true plateau was not 
reached for any cell line with up to 10uM Aza. IC50 represent dose at 50% of the maximal 
inhibition achieved. *Calculated IC50 values for A549 were ambiguous for all three experiments, 
but data were consistent. 
Cell Line Mean IC50 (+/- SD) Mean R
2 
(+/- SD) 
H358 4.111 +/- 0.132 0.9524 +/- 0.0071 
H460 0.953 +/- 0.170 0.9881 +/- 0.0048 
H838 2.497 +/- 0.270 0.9707 +/- 0.0038 
H1299 2.958 +/- 0.307 0.9393 +/- 0.0547 
H2170 1.552 +/- 0.063 0.9763 +/- 0.0111 
A549* 3.291 +/- 0.059 0.8133 +/- 0.0526 
 
Figure 2.  Sensitivity of NSCLC cell lines to azacitidine.  
Log dose response curves from representative experiments for NSCLC cell lines treated with Aza 
every 24h for 72h. Individual curves represent the percentage of viable cells (+/- standard 
deviation) normalized to untreated control cells within a given cell line, such that the mean 




































2.2 Dose combinations of Aza and entinostat generally do not synergistically impair cell 
viability in NSCLC cell lines 
 Preclinical studies have shown that the combination of a demethylating agent and 
a HDI can result in additive to synergistic inhibition of DNA synthesis and induction of 
apoptosis in vitro, and inhibition of tumor growth in vivo [106-109]. We aimed to 
determine whether the combination of Aza and entinostat synergistically impairs cell 
viability in NSCLC cell lines. We employed a previously published method for assessing 
the potential synergy of drug combinations [123]. We treated NSCLC cell lines in an 
eight by eight dosing matrix in 96-well plates, with entinostat varied along the y-axis and 
Aza varied along the x-axis, to provide dose combinations across a broad range of 
cconcentrations. Inhibition of cell viability or proliferation was assessed immediately 
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following treatment using the CellTiter-Glo viability assay or CellTiter AQueous One 
MTS proliferation assay (Promega).  
We first assessed whether the combination of Aza and entinostat was synergistic 
when administered concurrently during the final 24h of the 72h Aza treatment period. 
Cells were treated with Aza and entinostat increased in 3-fold increments up to 500uM 
and 5uM, respectively. Response matrices were generated by calculating and plotting 
inhibition Z at each dose combination relative to the mean of untreated cells (eight 
replicated). Representative response matrices for H358, H460, and H1299 are shown in 
Figure 3A (left panel). Entinostat treatment alone was relatively nontoxic until greater 
than 1uM doses were reached. In H1299 cells, even 5uM entinostat had little to no effect 
on cell viability. To determine whether the addition of entinostat to Aza treatment 
produced additive or synergistic inhibition of viability, highest single agent over response 
(HSA) plots were generated by subtracting from Z for a given dose combination the 
highest of the two single agent inhibition scores for the corresponding doses. The HSA 
model, also known as Gaddum’s non-interaction, deems synergy as an effect of 
combination that is greater than the effect of either constituent [124, 125]. HSA plots 
depicting excess inhibition of viability for a given dose combination are shown in Figure 
3A (right panel). Positive values indicate additivity or synergy, while negative values 
indicate antagonism. The greatest combinatorial effect was noted in H460 cells, with mild 
effects at moderate dose combinations, and more notable synergy at high dose 
combinations. In H358 cells, synergistic inhibition only occurred at very high dose 
combinations. Interestingly, the vast majority of dose combinations in H1299 were 
antagonistic, particularly at moderate to high doses of entinostat. Results in H838 and 
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H2170 were similar to H358, while results in A549 were similar to H1299 (data not 
shown). 
Given that Aza must be incorporated into DNA to actively inhibit DNMTs, and 
that HDAC inhibitor induced G1 arrest through activation of p21 would prevent DNA 
replication [70, 91], we hypothesized that administration of entinostat after Aza treatment 
would allow for greater incorporation of Aza into DNA and improve overall inhibition of 
cell viability. To this end, we performed dose combination matrix studies in which H358 
and H460 cells received entinostat for 24h after the 72h Aza treatment period, and 
proliferation of cells was assessed at 96h using the MTS assay. Lower maximal doses 
were used in these studies, with Aza increasing in 2-fold increments up to 5uM, and 
entinostat increasing in 3-fold increments up to 3uM. Dose combinations, administered 
sequentially, were actually less effective in H358 cells, with no evidence of synergy at 
even the maximum doses tested (Figure 3B upper). Sequential administration in H460 
was also slightly less effective compared to the previous schedule of administration 
(Figure 3B lower). 
  
Figure 3.  The combination of Aza and entinostat does not synergistically inhibit cell 
viability in NSCLC cell lines. A. Cells were treated with Aza every 24h for 48h, followed by 
dose combinations of Aza and entinostat for 24h, with each drug concentration increasing in 3-
fold increments along a given axis of the dosing matrix. Cell viability was assessed at 72h using 
the CellTiter-Glo assay, and luminescence values were corrected for background luminescence. 
Left  Response matrix depicting inhibition of cell viability for each well (ie. dose combination) of 
the matrix relative to the average of untreated wells (eight replicates). The red line represents the 
contour at which 50% inhibition occurs. Right  Response over highest single agent (HSA) matrix 
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displaying excess inhibition of viability for a given dose combination after subtraction of the 
highest of the two single agent inhibition scores for the corresponding doses. Negative values 
represent antagonistic response resulting from the combination. Independent experiments were 
repeated at least twice, with 1-2 plates per experiment, to ensure consistent results. Representative 
data for H358, H460, and H1299 shown. B. Cells were treated with Aza every 24h for 72h, 
followed by entinostat for 24h, with entinostat increasing 3-fold and Aza increasing 2-fold in 
concentration along the y-axis and x-axis of the dosing matrix, respectively. Proliferation was 
assessed at 96h using the CellTiter AQueous One MTS proliferation assay and measuring 
absorbance at 490nm. Left  Response matrix depicting inhibition of proliferation for each well 
(ie. dose combination) of the matrix relative to the average of untreated wells (eight replicates). 
Right  Response over highest single agent (HSA) matrix displaying excess inhibition of 
proliferation for a given dose combination after subtraction of the highest of the two single agent 
inhibition scores for the corresponding doses. Negative values (red) represent antagonistic 
response resulting from the combination. Independent experiments were repeated at least twice to 





















We then questioned whether optimal synergy would occur if both agents were 
administered concurrently during the first 24h of treatment, followed by Aza only for the 
reaming 48h. Given that lack of combinatorial benefit in H358, we selected this line for 
study. Cells were treated with either overlapping or sequential combination, and 
proliferated was assessed at 96h by MTS assay. Indeed, the overlapping combination 
resulted in greater inhibition of proliferation at lower doses of either drug compared to 
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sequential combination treatment (Figure 4A). For the overlapping combination, as doses 
of either drug increased, single agent inhibition became dominant and combinatorial 
benefit was lost. However, at moderate doses of Aza, administration of entinostat during 
the first 24h enhanced inhibition, Z, while administration after Aza treatment resulted in 
little change in proliferation (Figure 4B).  
 
Figure 4.  Overlapping, but not sequential, administration of the combination of Aza and 
entinostat has combinatorial activity against proliferation of H358 cells. H358 cells were 
treated with Aza every 24h for 72h, in combination with entinostat for the initial 24h of treatment 
(overlapping) or the 24h following Aza treatment (sequential), with entinostat increasing 3-fold 
and Aza increasing 2-fold in concentration along the y-axis and x-axis of the dosing matrix, 
respectively. Proliferation was assessed at 96h by MTS assay. A. Response matrices for 
overlapping (left) vs. sequential (right) administration depicting inhibition of proliferation for 
each well (ie. dose combination) of the matrix relative to the average of untreated wells (eight 
replicates). The red line represents the contour at which 50% inhibition occurs. B. Combination 
curves depicting the increase in inhibition Z resulting from the addition of entinostat (lower) 



























2.3 Epigenetic therapy exerts differential sustained effects on proliferation of NSCLC 
lines  
 To determine whether the anti-proliferative effects of epigenetic therapy are 
sustained after the end of treatment, we first treated cells every 24h with 500nM for 72h, 
and 50nM entinostat for the final 24h of the treatment period. At the end of treatment, 
cells were re-seeded, and the CellTiter-Glo viability assay was used to determine the 
number of viable cells present following growth for 5-7 days without drug. We selected 
the 500nM Aza since that concentration is sub-IC50 in all six cell lines, and has been 
shown to alter tumorigenic potential of breast, colon, and lung cancer cell lines without 
apparent toxicity in the same breast cancer cell line [86]. We chose 50nM entinostat since 
this represents a clinically achievable concentration [126]. Entinostat was given during 
the final 24h of the 72h Aza treatment period as a compromise between the overlapping 
and sequential 96h schedules previously tested in the H358 combination matrix 
experiments. The effects of Aza treatment on proliferation after treatment were varied 
among cell lines, with the most significant anti-proliferative effects in H358, H460, and 
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H2170 (Figure 5A and 5B). Interestingly, while H460 and H2170 represented the two 
most sensitive cell lines in our 3-day viability assays, H358 was one of the least sensitive 
cell line in that assay, exhibiting the highest IC50 and lowest maximal inhibition of 
viability at the end of Aza treatment. A549 cells, which appear to increase in proliferation 
with Aza treatment in the viability assay, were generally unaffected by epigenetic 
therapy. Similar to the combination matrix studies, Aza and entinostat inhibited 
proliferation in an additive manner in H460 cells, while the combination was antagonistic 
in H1299, and to a lesser extent, H838 cells (Figure 5A and 5B). Entinostat had no effect 
in the remaining cell lines. 
 
Figure 5.  Differential effects on proliferation of NSCLC cell lines following epigenetic 
therapy. Cells were treated with 500nM Aza every 24h for 72h, 50nM entinostat for 24h from 
hours 48-72 of the treatment period, combination, or mock. Immediately following treatment, 
cells were re-seeded at equal number and allowed to proliferate in drug-free media until day 8 
(H358, H2170), day 9 (H838, A549), or day 10 (H460, H1299). A. Percent viable cells, 
normalized to Mock, assessed using the CellTiter-Glo luminescence viability assay (Promega). 
Data shown for H2170, H838, H460, and H1299 are an average of two independent experiments, 
each with five replicates per condition. Data for H358 and A549 are from representative 
experiments with five replicates per condition. Statistical significance compared to mock 
determined by ANOVA with Dunnett’s multiple comparison test and denoted as follows: 
*p<0.05, ***p<0.001. Otherwise, differences were not significant (p>0.05). B. Qualitative effects 
of epigenetic therapy on proliferation of cells visualized by crystal violet staining of cells present 
on the day noted above for each cell line. Images shown are representative wells of 12-well plates 
































































































































































Published data suggests that Aza may deplete self-renewing or clonogenic cell 
populations in hematologic and breast cancer models [86]. To test whether treatment of 
cells with epigenetic therapy depletes clonogenic capacity of NSCLC cell lines, we 
assessed anchorage-dependent growth of colonies on Matrigel
TM
 following epigenetic 
therapy. We employed the same treatment and similar drug-free recovery regimen as 
used above in our studies of proliferation after epigenetic therapy. Inhibition of colony 
formation to a greater extent than the proliferative inhibition we observed in these cells 
lines may suggest a depletion of clonogenic potential, however we note that to confirm 
this, assays of anchorage-independent colony growth (ie. methylcellulose) would need 
conducted. To our surprise, inhibition of colony growth paralleled the trends of above 
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proliferative inhibition, but the magnitude of effect was generally reduced, suggesting 
that the effects on colony growth are driven by impaired proliferation of the general cell 
population, as opposed to depletion of a clonogenic subpopulation (Figure 6A and 6B).  
 
Figure 6.  Effects of epigenetic therapy on colony growth parallel effects on proliferation. 
Cells were treated with 500nM Aza every 24h for 72h, 50nM entinostat for 24h from hours 48-72 
of the treatment period, combination, or mock. Immediately following treatment, cells were 
seeded at equal number with five replicates on a solidified layer of Matrigel
TM
 and allowed to 
form colonies in the absence of drug. Colonies were stained with MTT reagent and colony 
number assessed on the day noted for each cell line. A. Representative wells depicting qualitative 
changes in colony growth. B. Percent colony formation (mean +/- SD) normalized to mock from 
representative H358, H460, H2170, and A549 experiments. Experiments were repeated at least 
twice to ensure consistent results. H838 and H1299 colony number could not be quantified as 
these cell lines did not form distinct colonies. Statistical significance compared to mock 
determined by ANOVA with Dunnett’s multiple comparison test and denoted as follows: 























































































































2.4 The cytotoxic effects of overlapping and sequential combination treatment are 
transient and peak at unique times in H358 
 The results of our studies of proliferation and colony formation after epigenetic 
treatment caused us to question whether increased cell death or cell cycle arrest may be 
responsible for the anti-proliferative effects observed. To address this question, we 
assessed cell cycle phase and cell death via sub-G1 population at the end of 96h 
epigenetic treatment, as well as three days and six days after treatment, in H358 cells. 
H358 cells were selected for several reasons. H358 cells were one of the least sensitive 
cell lines in our cell viability experiments, yet Aza treatment resulted in a sustained 
inhibition of H358 proliferation and colony growth after treatment comparable to the 
much more sensitive (in terms of IC50) H460 and H2170 cell lines. In addition, while 
50nM entinostat, administered during the final 24h of Aza treatment, had no effect in 
H358 cells, moderate dose combinations of Aza and entinostat, administered on the 
overlapping schedule, more effectively inhibited proliferation of H358 cells than Aza 
alone in combination matrix studies. Conversely, sequential administration of these same 
dose combinations did not yield benefit over Aza alone. Given that the effects of Aza on 
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proliferation do not fully manifest in short term viability studies, the 96h time point may 
have been too early to assess the combinatorial effects of late administration of entinostat 
with the sequential schedule. Therefore, we treated H358 cells with overlapping or 
sequential combination, as well as single agent Aza and entinostat, to not only address 
whether cytotoxicity or cell cycle arrest are responsible for the anti-proliferative effects 
of Aza, but also determine how schedule of administration of entinostat affects viability 
and cell cycle distribution. Cell cycle and sub-G1 analysis was at the end of treatment 
(96h), on day seven, and on day ten, to determine how long the anti-proliferative effects 
are sustained. We selected a dose of 500nM for entinostat since 50nM was insufficient to 
produce any effect in H358, and prior viability and proliferation studies suggested that 
this does would be relatively non-toxic in H358 cells. Analysis of the sub-G1 population 
at each time point revealed that cell death resulting from early administration of 
entinostat was greatest at 96h, while cell death due resulting from sequential 
administration was greatest at day seven (Figure 7A). In both cases, the magnitude of cell 
death was indistinguishable from control cells by day ten. Aza induced cell death was 
slightly higher at day seven, but was also transient. This may explain why inhibition of 
proliferation by at 96h was slightly more pronounced than inhibition of cell viability at 
72h in our MTS and CellTiter-Glo combination assays, respectively. Interestingly, the 
combinatorial effects were sub-additive regardless of schedule of administration. While 
cell death was observed following epigenetic treatment, no apparent accumulation in G1, 
S, or G2/M phases of the cell cycle were noted at days four, seven, or ten (Figure 7B and 
C, day 10 profiles not shown). Loss of cells in G1 was noted when sub-G1 populations 
were largest, suggesting that, if cells had temporarily arrested in G1, cell death occurred 
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relatively quickly. However, mitotic trapping of Aza treated cells with nocodazole also 
revealed no evidence of G1 or S phase arrest at day four, but instead a loss of G1 cells 
with concomitant increase in the sub-G1 population (Figure 8).  
 
Figure 7.  Overlapping and sequential combination treatment exert transient cytotoxic 
effects on H358 cells, but do not induce cell cycle arrest. H358 cells were treated in triplicate 
with 500nM Aza every 24h for 72h, in combination with 500nM entinostat for the initial 24h of 
treatment (overlapping) or the 24h following Aza treatment (sequential). Cell cycle phase 
distribution was assessed using flow cytometry to detect propidium iodide staining of DNA 
content. A. Percent of gated cells within the sub-G1 population at days 4 (immediately after 
treatment), 7, and 10. B. Representative cell cycle profiles at end of treatment (day 4). C. 
Representative cell cycle profiles on day 7, following three days in drug-free media. 
Sub-G1 Population














































































Figure 8.  Azacitidine does not induce G1 arrest in H358 cells. Cells were treated in triplicate 
with 500nM Aza every 24h for 72h. Cells were then cultured an additional 24 h in drug-free 
media, or treated with nocodazole (100 ng/mL) for 24h to trap cells in G2/M. Cells were then 
immediately ethanol fixed and cell cycle phase distribution was assessed using flow cytometry to 





2.5 Epigenetic therapy in vitro reactivated the key tumor suppressor gene, p16, and 
produced durable effects on tumorigenicity in vivo 
 Our results from the cell cycle experiments suggested that the cytotoxic effects of 
Aza and entinostat are transient, with cells exhibiting normal cell cycle profiles and 
viability within six days of the end of treatment. Our colleagues reported that in vitro 
treatment of breast, colon, and lung cancer cell lines 500nM Aza produced durable anti-
tumor effects in vivo, and demonstrated that this dose had minimal effects on viability 
and cell cycle phase in the same breast cancer cell line [86]. We employed a similar 
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experimental design to determine whether the Aza and combination treatment, while only 
transiently effecting cell viability, could produce durable impairment of tumorigenicity of 
H358 xenografts. To this end, we treated H358 cells every 24h for 72h with 500nM Aza, 
and administered 500nM entinostat for the final 12h of the treatment period. The 72h 
treatment schedule was chosen because overlapping versus sequential combination 
treated cells were indistinguishable in terms of viability and cell cycle profile by day ten. 
In addition, we reduced duration of entinostat treatment to decrease the early toxicity of 
combination treatment, since prior work has shown that HDI treatment for as short as 6-
12 hours, in combination DAC for 72h was sufficient to induce synergistic re-expression 
of silenced tumors suppressor genes [105]. After treatment, cells were rested in drug free 
media for four days prior to injection of treated cells into NOD/SCID mice on day seven 
to assess tumorigenicity. In parallel with assessment of H358 xenograft growth, we 
examined changes in methylation and expression of p16, which is epigenetically silenced 
by promoter hypermethylation in H358, to ensure our treatment regimen produces 
changes at the epigenetic level. Figure 9A shows demethylation of the p16 promoter with 
Aza treatment at days three and seven, with increased gene expression by day seven. 
Interestingly, the addition of entinostat did not augment p16 re-expression. Despite this, 
combination treatment resulted in greater inhibition (approximately 50% vs. 30%) of 
H358 xenograft growth than did Aza treatment (Figure 9B).  
To assess durability of the effects of epigenetic therapy on tumorigenicity of 
H358, we harvested and pooled tumors within each group, and generated single cells 
suspensions for injection into a secondary group of NOD/SCID mice. Animals were 
injected with 10
4
 viable cells each to assess both tumor take rate and tumor growth. 
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Tumor take rated was unaffected by epigenetic therapy, with 1/9 mock, 1/8 combination, 
and 2/10 Aza injections not producing tumors. Conversely, Aza and combination tumor 
growth remained significantly inhibited compared to mock tumor growth by week nine 
after injection (Figure 9C). The durability of these effects is particularly striking given 
the short duration of in vitro epigenetic treatment and the length of time that lapsed (>4 
weeks) prior to secondary transplant.  
 
Figure 9.  Epigenetic therapy in vitro reactivates the tumor suppressor gene p16 and exerts 
durable anti-tumor effects against H358 xenografts in vivo. H358 cells were treated 500nM 
Aza every 24h for 72h, with or without 500nM entinostat for the final 12h of the 72h treatment 
period. Cells were harvested at the end of treatment on day 3, reseeded at equal number for each 
condition, and cultured in drug-free media for four days. A. Upper  Methylation specific PCR 
(MSP) depicting complete methylation of the p16 promoter at days 3 and 7, as evidence by the 
absence of unmethylated (U) PCR product. Treatment with 500nM Aza results in appearance of 
unmethylated product and reduction in methylated (M) product, indicating demethylation of p16 
at days 3 and 7. Lower  Quantitative RT-PCR from triplicate reactions depicting reactivation of 
p16 expression following Aza and combination (Aza and entinostat) treatment, with peak 
expression occurring on day 7. B. On day 7, cells at equal number per condition were injected 
subcutaneously into the hind flank of NOD/SCID mice (2x10
6
 viable cells/mouse). Growth of 
H358 xenografts following transient in vitro exposure to Aza, with or without entinostat, shown 
as mean tumor volume +/- SEM. Statistical significance compared to mock determined by two-
way ANOVA with Bonferroni posttests. C. Tumors within each group were harvested and 
pooled. Single cells suspensions were generated and cells at equal number per condition were 
injected into a second group of NOD/SCID mice (10
4
 viable cells/mouse). Points represent 
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individual tumor volumes nine weeks post injection. Statistical significance determined by 
ANOVA with Dunnett’s multiple comparison test. 
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2.6 Reactivation of p16 is not critical for anti-tumor efficacy of epigenetic therapy in 
H358 xenografts 
 There is considerable evidence that methylation and silencing of p16 is a critical 
step in the development of NSCLC, particularly the high incidence and early occurrence 
of p16 silencing, as well as the critical role for p16 in the regulation of cell cycle 
progression [31-33, 35, 36]. Since p16 is densely hypermethylated and transcriptionally 
silenced in H358 cells, and our work demonstrated that treatment with Aza alone or in 
combination with entinostat resulted in both p16 gene re-expression and anti-tumor 
efficacy, we hypothesized that, if p16 reactivation plays a key role important in anti-
tumor response, knockdown of p16 with shRNA would both prevent gene reactivation 
after Aza treatment and abrogate anti-tumor efficacy. To test this, we first screened six 
shRNAs directed at p16 in H596 cells, which overexpress p16 protein as a result of a 
mutation in Rb, to select the optimal shRNA. Oligo 82 results in complete knockdown of 
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p16 in H596 cells, as shown by Western blot (Figure 10A). We then generated H358 cell 
lines expressing shRNA oligo 82 (p16_82) or scramble control (scram), and treated cells 
with mock, Aza, or the combination of Aza and 50nM entinostat, with entinostat 
administered to cells during the final 24h of Aza treatment. We returned to 50nM 
entinostat given its clinical relevance over higher doses. We assessed p16 transcript 
levels on day 7, and found that Aza and combination treatment reactivated p16 
expression in scram cells, but not p16 knockdown cells, although a minor increase in 
expression was noted in p16_82 cells treated with combination (Figure 10B, upper). We 
then examined protein levels of p16 on day 7. Despite reactivation of p16 transcript in 
scram cells, protein was undetectable by Western blot (Figure 10B, lower). Given that 
H358 cells normally completely silence p16, we considered the possibility that the level 
of p16 protein tolerable by H358 cells may be below the limit of detection, and proceeded 
to assess whether knockdown of p16 transcript reactivation abrogated inhibition of 
colony formation or tumorigenicity of H358. Colony formation on Matrigel
TM
 was 
inhibited equally by Aza and combination in both scram and p16_82 cells (Figure 10C). 
Moreover, tumorigenicity of both scram and p16_82 H358 xenografts was impaired to a 
similar degree (Figure 10D). These data suggest that p16 re-expression is not important 
for Aza induced anti-tumor response in H358 xenografts, either because the protein itself 
is not expressed following upregulation of transcript, or the undetectable amount of 
protein that is expressed in scram cells does not contribute to anti-tumor response. 
 
Figure 10.  Reactivation of p16 is not critical for anti-tumor efficacy of epigenetic therapy in 
H358. A. Short hairpin RNA (shRNA) oligos directed at p16 transcript were screened in H596 
cells, which overexpress p16 as a result of  a mutation in Rb. Cells expressing p16 or scrambled 
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control (scram) shRNA were generated by lentiviral infection and selection with puromycin. 
Western blots show knockdown of p16 protein by oligo 82. B. H358 cells expressing p16_82 or 
scram shRNA were treated with mock, 500nM Aza every 24h for 72h, or the combination of Aza 
with 50nM entinostat for the final 24h. Upper  Quantitative RT-PCR from triplicate reactions 
depicting reactivation of p16 expression on day 7 in scram cells treated with Aza or combo, but 
prevention of gene reactivation in p16_82 knockdown H358 cells. Lower  Western blots 
depicting a lack of detectable p16 protein in scram cells despite reactivation of transcript. C.  
Epigenetic treated H358 scram and p16_82 knockdown cells were seeded at equal number on 
solidified Matrigel
TM
 on day 10 to assess colony formation, with four replicates per condition. 
Data shown as percent colony formation with standard deviation. No differences in inhibition of 
colony growth by Aza and combo treatment were observed between scram and p16_82 cells. D. 
Mock and Aza treated H358 scram and p16_82 knockdown cells were injected subcutaneously 
into the right hind flank of NOD/SCID mice on day 10 to assess growth of xenografts tumors 
(mock, n=7; Aza, n=8). No significant difference in inhibition of tumor growth by Aza 










































































2.7 Epigenetic therapy exerts differential effects on tumorigenicity of NSCLC xenografts 
 The finding that in short, 3-day in vitro treatment with epigenetic therapy reduced 
tumorigenicity of H358 xenografts prompted us to expand the tumorigenicity studies to 
our entire panel of cell lines. Again, cells were treated every 24h for 72h with 500nM 
Aza or mock, and given 50nM entinostat or mock for the final 24h. Cells were rested in 
drug free media for seven days and then injected into both flanks of NOD/SCID mice, 
with five mice per arm for a total of n = ten tumors. Interestingly, the epigenetic therapy 
exerts differential effects on tumorigenicity of these cell lines (Figure 11), and the results 
of our in vitro studies are not directly predictive of these effects. H358 is one of the least 
sensitive cell lines to Aza in 72h viability experiments, yet exhibit pronounced 
proliferative inhibition after Aza treatment. Here, a statistically significant reduction in 
tumorigenicity by Aza, with or without entinostat (p<0.001 for both), mirrors the 
sustained effects of Aza on proliferation after treatment. Similarly, modest combinatorial 
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benefit was observed in H460 xenografts, following the trend observed in combination 
matrix, post treatment proliferation, and colony formation studies, however the effects of 
Aza and combination therapy on tumorigenicity were less pronounced than effects 
achieved in vitro. More interesting are the results in H2170 and H1299 xenografts. Based 
on cell viability experiments, H2170 is the second most sensitive line to Aza. In addition, 
H2170 proliferation and colony growth were significantly impaired post Aza treatment. 
Conversely, the effects of Aza or combination therapy on H2170 tumor growth were 
minimal, and statistically insignificant. H1299 xenograft growth was moderately 
inhibited by Aza alone (p<0.001), but substantially inhibited by combination epigenetic 
therapy (p<0.001). This is particularly interesting given that H1299 cells are relatively 
insensitive to Aza treatment in viability assays, and that combination treatment was 
antagonistic in H1299 in vitro. In tumorigenicity studies, in addition to all in vitro 
studies, A549 is unaffected by epigenetic treatment. We were unable to assess the effects 
of epigenetic therapy on tumorigenic potential of H838 as we were unable to efficiently 
establish H838 xenografts, even from mock cells, despite multiple attempts. 
 
Figure 11.  Effects of in vitro epigenetic therapy on tumorigenicity of NSCLC xenografts. 
Cells were treated with 500nM Aza every 24h for 72h, 50nM entinostat for 24h from hours 48-72 
of the treatment period, combination, or mock. Immediately following treatment on day 3, cells 
were re-seeded at equal number and cultured in the absence of drug for seven days. On day 10, 
cells at equal number were injected subcutaneously into left and right hind flanks of five female 
NOD/SCID mice per condition (n=10 tumors). Curves represent mean tumor volume +/- SEM for 
each epigenetic pretreatment condition. Statistical significance compared to mock determined by 
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two-way ANOVA with Bonferroni posttests. Otherwise, differences were not significant 
(p>0.05). 
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  Using a sub-IC50 dose of Aza, and a low, but clinically achievable, 50nM 
concentration of entinostat, we demonstrated differential effects on long term 
tumorigenic potential of xenografts established from in vitro treated NSCLC cell lines, 
without clear association with acute cytotoxic response to Aza or combination treatment. 
In addition, results of short term viability assays and longer term studies of proliferation 
and colony growth in vitro did not correlate in several cell lines. Interestingly, in two cell 
lines exhibiting some of the lowest “sensitivity” to Aza in standard cell viability assays, 
H358 and H1299, in vitro treatment with Aza produced significant anti-tumor effects in 
vivo. In contrast, H460 and H2170 xenografts were only modestly affected by Aza, 
despite these cell lines representing the two most “sensitive” lines in 72h viability assays. 
Perhaps most striking were the results of combination therapy in H1299. While the 
combination of Aza and entinostat was antagonistic in H1299 cells in our combination 
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matrix viability studies and in studies of post treatment proliferation, tumorigenic 
potential of H1299 xenografts was dramatically reduced by combination therapy.  
We also demonstrated combinatorial activity in H358 xenografts established from 
cells treated in vitro with Aza and the higher (but shorter duration), 500nM dose of 
entinostat. Tumor growth was inhibited by approximately 50%, compared to 
approximately 30% for Aza alone. Sub-G1 analysis of H358 cells at day seven revealed 
increased cell death in cells that received 500nM entinostat after treatment with Aza 
(sequential administration) compared to Aza only treated cells. In addition, cell death 
resulting from Aza treatment was increased at day seven compared to day four. While in 
this study, duration of entinostat treatment was reduced to 12hr (vs. 24h), and 
administration was moved to the final 12h of the 72 Aza treatment period, it is possible 
that, similar to the results of sub-G1 analysis, tumors grown from combination treated 
cells exhibited increased cytotoxicity at the time of injection (day seven), and as a result, 
greater tumor growth inhibition was observed, compared to Aza treatment alone. 
However, we noted that the growth of tumors in both groups tracked closely for the first 
two weeks after injection. Then, the growth rate of Aza tumors increased relative to 
combination treated tumors. Since our cell cycle data also demonstrated a return to 
normal viability by day ten, it is unlikely that cytotoxicity alone accounts for the anti-
tumor effects of both groups, or for the greater effects of combination treatment. In 
addition, serial transplant of these tumor cells showed the effects on tumor growth were 
extremely durable. Lastly, Aza still elicited a strong anti-tumor effect in H358 cells that 
were injected into mice seven days after treatment, the time point by which H358 cells 
exhibited viability similar to control cells. 
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Combinatorial epigenetic therapy has already shown promising clinical activity, 
eliciting major objective responses in a small subset of patients [114]. While the 
mechanisms that drive clinical efficacy of epigenetic therapy in lung cancer remain 
unknown, and controversial, insight into these mechanisms is slowly being gleaned from 
preclinical work, such as studies that demonstrated that relatively low doses of 
demethylating agents could impair the clonogenic and tumorigenic capacity of leukemia 
and breast cancer cell lines, while simultaneously reactivating tumor suppressor genes 
and restoring critical regulatory pathways [86]. While epigenomic studies have not yet 
been completed, our results strongly suggest the efficacy in our xenografts models is 
being mediated through non-cytotoxic mechanisms. 
 
4. Materials and Methods 
Cell lines and Reagents 
NCI-H358, NCI-H460, NCI-H838, NCI-H1299, NCI-H2170, A549, and NCI-H596 were 
obtained from the American Type Culture Collection (ATCC) and cultured in RPMI-
1640 supplemented with 10% FBS, penicillin/streptomycin, 2 mmol/L l-glutamine, 1 
mmol/L sodium pyruvate, 10 mmol/L HEPES buffer, and 1.5 g/L sodium bicarbonate. 
Cells were cultured in a humidified incubator at 37ºC with 5% CO2. 
 
Drugs and Reagents 
5-azacitidine (Aza) was purchased from Tocris Bioscience, dissolved in 1x PBS as a 
4mM stock, and stored at -80ºC in aliquots. Fresh aliquots of Aza were thawed 
immediately prior to use. Entinostat was provided by Syndax Pharmaceuticals and stored 
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at -20ºC in a desiccator. A 20mM stock solution and serial dilutions to 200uM in DMSO 
were made and stored at -20ºC. Drug was thawed immediately prior to use and diluted 
1:4000 in culture media to provide the desired concentration of entinostat and 0.025% 
DMSO in media.  
 
Cell viability assays 
Cells were seeded in opaque walled 96-well plates as follows: H358 = 4200 cells/well, 
H460 = 1000 cells/well, H838 = 1700 cells/well, H1299 = 1000 cells/well, H2170 = 4200 
cells/well, A549 = 1700 cells/well. Approximately 24h later, cells were treated with the 
following concentrations of Aza with five replicates per each: 0nM, 10nM, 30nM, 
100nM, 300nM, 1uM, 3uM, and 10uM. Cells were retreated every 24h for 72h. 
Following treatment, ATP content was measured as an indicator of cell viability using the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega). Cells were incubated with 
prepared CellTiter-Glo reagent for 10 min at room temperature, and luminescence was 
read on a SpectraMax M2e plate reader (Molecular Devices). Raw data were corrected 
for background luminescence, transformed (x=log(x)), and analyzed by nonlinear 
regression using the equation, log(inhibitor) vs. response with variable slope in GraphPad 
Prism 5 to obtain IC50 values and R
2
. Experiments were repeated at least twice, and 
mean IC50 and R
2 
with standard deviation are provided. Log dose response curves were 
generated by normalizing transformed data to 0nM control wells and analyzing 
normalized data by nonlinear regression using the equation, log(inhibitor) vs. response 




Synergy matrix assays 
For 72h treatment experiments, cells were seeded in opaque walled 96-well plates in a 
nine well by eight well matrix as follows: H358 = 4200 cells/well, H460 = 1000 
cells/well, H838 = 1700 cells/well, H1299 = 1000 cells/well, H2170 = 4200 cells/well, 
A549 = 1700 cells/well. Approximately 24h after plating, cells were treated with Aza 
every 24h for 48h, followed by dose combinations of Aza and entinostat for 24h, with 
each drug concentration increased in 3-fold increments along a given axis of the dosing 
matrix. Cell viability was assessed at 72h using the CellTiter-Glo assay (Promega). Raw 
data were corrected for background luminescence and inhibition, Z, was calculated for 
each well using the equation, Z = (1-T/C)*100, where T equals the background corrected 
luminescence for a given well (ie. dose combination) and C equals the mean background 
corrected luminescence of eight untreated control wells. Inhibition scores were plotted in 
a response matrix. Next, a response over highest single agent (HSA) matrix was 
generated by subtracting the highest Z for each single agent in the corresponding row and 
column from Z for a given dose combination. Independent experiments were repeated at 
least twice, with 1-2 plates per experiment, to ensure consistent results, and 
representative data shown. For 96h treatment experiments, H358 and H460 cells were 
seeded at 3200 cells/well and 1000 cells/well, respectively, in a nine well by eight well 
matrix in 96-well plates. Cells were treated with Aza every 24h for 72h, with the 
concentration of Aza increased in 2-fold increments along the x-axis of the matrix. Cells 
were treated with entinostat either during the first 24h (overlapping) or for 24h following 
Aza treatment (sequential), with the concentration of entinostat increased in 3-fold 
increments along the y-axis of the matrix. Proliferation was assessed at 96h using the 
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CellTiter AQueous One MTS proliferation assay (Promega) and absorbance at 490nm 
measured on a SpectraMax M2e plate reader (Molecular Devices). Response and HSA 
matrix plots were generated as described above. Experiments were repeated at least twice 
to ensure consistent results, and representative data shown. 
 
Cell cycle assay following epigenetic therapy 
H358 cells were seeded at 9.6 x 10
4
 cells/well in 6-well plates and allowed to adhere for 
approximately 24h. Cells then were treated in triplicate with 500nM Aza or mock (1x 
PBS) in fresh media every 24h for 72h. Cells received 500nM entinostat during the first 
24h of treatment (overlapping) or for 24h following treatment with Aza (sequential). 
Cells that did not receive entinostat were mock treated with 0.025% DMSO. All media 
was saved in separate 6-well plates after removal from cells. At the end of treatment, 
cells were washed and harvested. Saved media, washes, and cells for each replicate were 
pooled and centrifuged 5 min at 300 x g. Cells were washed in 2mL 1% FBS/1x PBS and 
centrifuged again. Cells were resuspended in 1mL cold 1x PBS, and fixed in 9mL cold 
70% ethanol for at least 24h at 4°C. Fixed cells were centrifuged at 300 x g for 5 min, 
resuspended in 1.5mL of a 2:1 mix of 1% FBS/1x PBS and phosphate citric acid buffer 
(pH 7.8), and incubated for 5 min at RT. After centrifugation and removal of supernatant, 
cells were resuspended in 300uL of PI staining solution (10ug/mL propidium iodide and 
3 K.U. of RNase A in 1% FBS/1x PSB) and incubated at 37°C for 30 min. Flow 
cytometry was performed to detect propidium iodide staining of DNA. Ten thousand PI 
positive gated events were collected for each sample. Similarly, cells that received 
66 
 
epigenetic therapy and were cultured in drug free media until day 7 and day 10 time 
points were also harvested, fixed, and analyzed as described. 
 
H358 tumorigenicity and serial transplant  
H358 cells were seeded at 3 x 10
6
 cells per T75cm
2
 flask. Approximately 18h later, cells 
were treated with 500nM Aza or mock (1x PBS) in fresh media every 24h for 72h. 
During the final 12h of the 72h treatment period, Aza treated cells received either 500nM 
entinostat or 0.05% DMSO, and mock treated cells received 0.05% DMSO. Cells were 
harvested at the end of treatment on day 3, reseeded at equal number, and cultured for 
four days in drug free. On day 7, cells were harvested, counted, and suspended in a 50:50 
mix of 1x PBS and Matrigel
TM
. Female NOD/SCID mice, 5-7 weeks old, were then 
injected subcutaneously in the right hind flank with a 100uL volume containing 2 x 10
6
 
viable cells. Tumor volume measurements were calculated as (L x W
2
)/2. Statistical 
significance compared to mock was determined by repeated measures two-way ANOVA 
with Bonferroni posttests in GraphPad Prism 5. On day 29 post injection, tumors within 
each group were pooled and mechanically disrupted to generate single cell suspensions. 
Cells were injected into a second cohort of NOD/SCID mice at 10
4
 viable cells per 
injection. Statistical significance at week 9 post injection was determined by ANOVA 
with Dunnett’s multiple comparison test in GraphPad Prism 5. Protocols for these 
experiments were approved by the John Hopkins University Animal Care and Use 
Committee and were strictly followed. 
 
Methylation specific PCR (MSP) to detect p16 methylation  
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DNA was isolated from H358 cells at 72h and at day seven using the Qiagen DNA Mini 
kit. Quantity and purity were assessed by measuring absorbance at 260nm and 280nm on 
the NanoDrop spectrophotometer (Thermo Scientific). Bisulfite conversion of 1ug of 
DNA per sample was performed using the Zymo EZ DNA methylation kit. MSP was 
performed on the IQ5 thermal cycler (Bio-Rad) using p16 primers and conditions as 
previously described [127]. PCR products were visualized on a 2% agarose gel with 
GelStar™ Nucleic Acid Gel Stain (Lonza).  
 
Quantitative RT-PCR to detect p16 gene expression 
RNA was isolated using TRIzol® and provided protocol (Life Technologies). Quantity 
and purity were assessed by measuring absorbance at 260nm and 280nm on the 
NanoDrop spectrophotometer (Thermo Scientific). cDNA was synthesized from 1ug of 
RNA using the Quantitect Reverse Transcription Kit and provided protocol (Qiagen). 
PCR using template cDNA, iQ SYBR Green Supermix, and standard thermocycling 
conditions was performed on the IQ5 thermal cycler and real-time detection system (Bio-
Rad). Primers for p16 and GAPDH were previously published [21, 128]. p16 expression 
was normalized to GAPDH for each sample. 
 
shRNA knockdown of p16 
Lentiviral particles were generated in 293T cells (2.5 x 10
6
 cells per T25 flask) and H596 
and H358 cells were infected according to The RNAi Consortium (TRC) Library 
Production and Performance Protocols (Broad Institute) [129]. p16 shRNA constructs 
were obtained from TRC. The pLKO.1-scramble control vector (Addgene plasmid 1864) 
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was kindly provided by Dr. Timothy F. Burns. Selection with 0.5ug/mL puromycin began 
24h after infection. 
 
Western blot for p16 
Protein was isolated from H358 cell pellets rinsed with 1x PSB and lysed in 1x RIPA 
buffer containing protease and phosphatase inhibitors (Sigma). Protein was quantified 
using the BCA Protein Assay (Thermo Scientific Pierce) and measuring absorbance at 
562nm on the SpectraMax M2e plate reader (Molecular Devices). Proteins were resolved 
by electrophoresis on 12% NuPAGE® Bis-Tris Gels (Life Technologies). Proteins were 
transferred to a PVDF membrane, and blots were blocked for 1h at RT in 5% milk/0.2% 
TBST. Blots were probed with p16 and GAPDH primary antibodies (Cell Signaling 
Technologies) at 1:1000 in 5% milk/0.2% TBST, overnight at 4°C. Blots were then 
washed 4 x 5min at RT with 0.1% TBST (GAPDH) or 0.2% TBST (p16). Blots were 
probed with anti-Rabbit HRP secondary antibody for 90 min at RT, then washed again as 









 Prime (p16) (GE Healthcare). 
 
Treatment of cell lines with epigenetic therapy for proliferation, colony formation, and 
tumorigenicity studies 
H358, H460, H838, H1299, H2170, and A549 cells were seeded at 1 x 10
6





, 2 x 10
5
, 1 x 10
6
, and 3.5 x 10
5
 cells per 75cm
2
, respectively, and allowed to 
adhere approximately 20-24h. Cells were then treated with 500nM Aza or mock (1x PBS) 
in fresh media every 24h for 48h, then treated with 500nM Aza, 50nM entinostat, 
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combination, or mock (1x PBS) for the final 24h of treatment. All treatments contained a 
final of 0.025% DMSO for the final 24h treatment.  
 
Assessment of proliferation following epigenetic therapy 
Following 72h epigenetic treatment, cells were seeded in opaque walled 96-well plates 
with five replicates per condition, as follows: H358 = 1000 cells/well, H460 = 500 
cells/well, H838 = 1000 cells/well, H1299 = 500 cells/well, H2170 = 1500 cells/well, 
A549 = 1000 cells/well. Cells were cultured 5-7 days in the absence of drug. The number 
of viable cells present was then determined using the CellTiter-Glo assay (Promega). 
Data were corrected for background absorbance and normalized to mock to determine the 
percent of viable cells present. Data for H460, H838, H1299, and H2170 represent an 
average of normalized data from two independent experiments. Data for H358 and A549 
are from a single experiment, as prior experiments for H358 and A549 using the CellTiter 
AQueous One MTS assay produced similar results. Statistical significance for each 
condition compared to mock was determined in GraphPad Prism 5 using ANOVA with 
Dunnett’s multiple comparison test. 
 
Crystal violet staining of proliferating cells after epigenetic therapy 
Following 72h epigenetic treatment, cells were seeded in 12-well plates in triplicate, as 
follows: H358 = 2 x 10
4
 cells/well, H460 = 5000 cells/well, H838 = 10
4
 cells/well, 
H1299 = 5000 cells/well, A549 = 10
4
 cells/well. Cells were cultured 5-7 days in the 






 colony formation assay 
Following 72h epigenetic treatment, cells were seeded on a 40uL layer of solidified 
Matrigel
TM
, with five replicates per condition, as follows: H358 = 2000 cells/well, H460 
= 500 cells/well, H838 = 1000 cells/well, H1299 = 500 cells/well, H2170 = 1500 
cells/well, A549 = 1000 cells/well. Colonies were grown 5-9 days, stained with MTT 
reagent, and imaged and counted on the GelCount
TM
 colony counter (Oxord Optronix). 
Colony number was normalized to mock to determine % colony formation. Experiments 
were repeated at least twice, with the exception of H838 and H1299 which did not form 
distinct colonies and could not be quantified. Statistical significance for each condition 
compared to mock was determined in GraphPad Prism 5 using ANOVA with Dunnett’s 
multiple comparison test. 
 
Xenograft tumorigenicity experiments 
Following epigenetic treatment, cells were cultured for seven days in drug free media. On 
day 10, cells were harvested, counted, and injected subcutaneously into the left and right 
hind flank of 5-7 week old female mice, in a total volume of 100uL, consisting of a 50:50 
mix of 1x PBS and Matrigel
TM
. Cell numbers per injection were as follows: H358 = 3.5 x 
10
5
, H460 = 2 x 10
5
, H1299 = 2 x10
5
, H2170 = 3.35 x 10
5
, and A549 = 1.5 x 10
5
. Tumor 
volume measurements were calculated as (L x W x H). Statistical significance compared 
to mock was determine by repeated measures two-way ANOVA with Bonferroni 
posttests in GraphPad Prism 5. Protocols for all animal experiments were approved by the 




III. Epigenetic therapy as a primer for subsequent chemotherapy 
1. Introduction 
 Lung cancer remains a dominant public health burden as the leading cause of 
cancer-related mortality worldwide [1]. Non-small cell lung cancer (NSCLC) accounts 
for approximately 80% of all lung cancer cases, and comprises several histological 
subtypes, including adenocarcinoma, squamous cell carcinoma, and less commonly, large 
cell carcinoma. The high incidence of NSCLC cases and poor prognosis necessitate 
research to define novel and more effective treatment options. Treatment of 
adenocarcinoma has advanced in recent years with mutational characterization and the 
development of targeted therapies against EGFR and ALK [3-5]. However, many 
NSCLC patients do not harbor EGFR mutations or ALK fusions, and are unlikely to 
benefit from these agents. In addition, acquired resistance and disease recurrence also 
limit their utility [7-9]. As a result, NSCLC is still frequently treated with conventional 
cytotoxic chemotherapy, which is often hampered by limited efficacy, high toxicity, and 
again, resistance and recurrence of disease. 
 There is a wealth of evidence (reviewed elsewhere, and outlined in the 
introductory chapter of this thesis) that epigenetic dysregulation, including silencing of 
tumors suppressor genes, is intimately involved in lung carcinogenesis [33, 130]. 
Recently, epigenetic therapy has garnered considerable interest as a promising 
therapeutic option for NSCLC following the results of a phase I/II trial of the 
combination of the demethylating agent, azacitidine (Aza), and the class I specific histone 
deacetylase inhibitor (HDI), entinostat (MS275), in advanced stage disease [114]. While 
only a small number of patients (2/34) exhibited objective responses to combination 
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epigenetic therapy alone, some of these responses were surprisingly durable, with two 
patients experiencing disease stabilization for 14 and 18 months. Also intriguing was the 
observation that several patients, including some who progressed quickly on epigenetic 
therapy, responded surprisingly well to subsequent chemotherapy (Figure 12), despite a 
median of three prior therapies for this patient population. Two patients survived 44 and 





Figure 12.  Maximal change in tumor size in response to subsequent chemotherapy 
following combinatorial epigenetic therapy. Green bars represent objective responses by 
RECIST criteria to specified subsequent treatment regimen as measured by the % change in 
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maximal diameters of target lesions. Blue bars represent disease stabilization, while red bars 
indicate disease progression. Graphs updated from Juergens et al., 2011. 
 
 Interestingly, a similar scenario was previously observed in a pilot phase I/II 
study of decitabine in stage IV NSCLC patients, with one patient receiving chemotherapy 
roughly six months after treatment with the demethylating agent, decitabine (DAC), and 
surviving 81 months [87]. Although comprising only a small number of patients, these 
observations suggest the potential for epigenetic therapy to sensitize NSCLC to 
subsequent chemotherapy. While not yet formally tested in NSCLC, supporting clinical 
evidence for a priming effect does exist for solids tumors. Two recent trials demonstrated 
that treatment with a demethylating agent (Aza or DAC) sensitizes resistant and 
refractory ovarian tumors to platinum chemotherapy [121, 122].  
Preclinical evidence is also mounting describing the involvement of epigenetic 
mechanisms in drug resistance in cancer [115, 116, 118, 131, 132], and several studies 
have demonstrated sensitization of solid cancers to chemotherapy following treatment 
with epigenetic based therapies, in association with reactivation of silenced tumor 
suppressor genes or restoration of tumor suppressor protein expression [116, 117, 131]. 
Interestingly, one of these studies found that the combination of DAC and the pan-HDI, 
belinostat, was more effective than decitabine alone at reactivating the silenced tumor 
suppressor, hMLH1, and sensitizing a cisplatin resistant ovarian cancer cell line to 
cisplatin, both in vitro and in vivo [131]. Another recent paper directly implicated an 
epigenetic mechanism involving increased expression of the histone demethylase, 
JARID1A/KDM5A, and loss of H3K4me2/me3 histone marks, in tolerance of a mutant 
EGFR NSCLC line to EGFR targeted therapy, and demonstrated the ability to prevent or 
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suppress the phenotype through treatment with HDIs [118]. These latter two studies 
highlight a distinct role for histone deacetylase (HDAC) inhibition, in addition to DNA 
demethylation, in reversal of epigenetically mediated resistance mechanisms.  
Here we test, using several preclinical models encompassing the three most 
common histological subtypes, whether priming with single agent or combination 
epigenetic therapy sensitizes NSCLC to various subsequent chemotherapeutic agents. We 
find that the combination of azacitidine and entinostat enhances sensitivity of select 
NSCLC tumors to irinotecan in vivo, while sensitivity to other chemotherapeutic agents 
remains largely unaffected both in vitro and in vivo.   
 
2. Results 
2.1 Epigenetic therapy does not sensitize NSCLC cell lines to subsequent chemotherapy 
in acute cytotoxicity assays 
We aimed to determine whether epigenetic therapy sensitizes NSCLC cell lines to 
subsequent chemotherapy in vitro. We selected H1299 (large cell carcinoma), H358, 
H838, and A549 (all adenocarcinoma) for study.  We first treated cell lines with 500nM 
Aza every 24 hours for 72 hours (days 0-3), 50nM entinostat for 24 hours (days 2-3), 
combination, or mock treatment. At the end of treatment on day 3, cells were harvested, 
reseeded, and rested in drug free media for one week prior to exposure to various 
chemotherapeutic agents on day 10. Cisplatin, docetaxel, gemcitabine, and vinorelbine 
were selected as they are FDA approved for the treatment of NSCLC. Two additional 
agents, the hsp90 inhibitor, 17-AAG, and the proteasome inhibitor, bortezomib, were also 
included. It has been shown in breast cancer that HDAC1 maintains the chaperone, 
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hsp90, in a deacetylated state, allowing its association with and preventing proteasomal 
degradation of DNA methyltransferase 1 (DNMT1). HDAC1 inhibition induces hsp90 
hyperacetylation, disrupts association of hsp90 with DNMT1, and promotes 
ubiquitination and degradation of DNMT1 via the proteasome [58]. Since HDAC1 is a 
target of entinostat, we hypothesized that pretreatment with entinostat may augment 
sensitivity to 17-AAG.  
Pretreated cells were seeded at equal number in 96-well plates on day 9, and 
treated with chemotherapy for 72h beginning on day 10. Following treatment, cell 
viability was immediately assessed using the CellTiter-Glo luminescence viability assay, 
with three replicates per dose tested. Raw data values were corrected for background 
luminescence to represent the total number of viable cells present. The chemotherapy 
dose range was then transformed to a log scale (x=log(x)). Nonlinear regression of 
corrected, transformed data was performed using the equation, log(inhibitor) vs. response 
with variable slope, to obtain IC50 values, 95% confidence intervals, and R
2
 for each 
epigenetic pretreatment condition and chemotherapy tested (Table 4). In cases where a 
maximal inhibition plateau was not reached and the calculated IC50 was ambiguous 
(H358 and H838 cisplatin), IC50 was considered not determined (ND). Experiments were 
repeated at least twice, with the exception of vinorelbine for H358 and H1299, where no 
notable differences were observed. Statistical analysis of logIC50 and standard error of 
logIC50 via ANOVA with Tukey’s multiple comparison test revealed no statistically 





Table 4. Calculated IC50 values for chemotherapy following epigenetic priming.  
IC50, 95%CI, and R
2
 calculated from representative experiments with three replicates per dose 
tested. No statistically significant differences in IC50 by ANOVA with Tukey’s Multiple 
Comparison Test were observed. ND denotes IC50 values were not determined. 




H1299 Mock 99.29nM 92.06 to 107.1 0.9951 
 Entinostat 94.44nM 86.83 to 102.7 0.9961 
 Aza 93.99nM 82.25 to 107.4 0.9907 
 Combination 102.0nM 91.60 to 113.6 0.9898 
H358 Mock 42.19nM 29.45 to 60.43 0.9213 
 Entinostat 31.56nM 28.13 to 35.41 0.9848 
 Aza 41.49nM 33.84 to 50.88 0.9709 
 Combination 37.57nM 33.71 to 41.87 0.9902 
A549 Mock 46.38nM 37.55 to 57.29 0.9828 
 Entinostat 44.42nM 35.82 to 55.08 0.9814 
 Aza 34.28nM 28.15 to 41.74 0.9710 
 Combination 37.62nM 31.07 to 45.56 0.9901 
Bortezomib 
H1299 Mock 5.616nM 5.057 to 6.238 0.9966 
 Entinostat 6.000nM 5.252 to 6.855 0.9960 
 Aza 5.996nM 5.714 to 6.292 0.9993 
 Combination 5.862nM 5.267 to 6.524 0.9959 
H358 Mock 4.648nM 3.882 to 5.564 0.9831 
 Entinostat 4.342nM 3.880 to 4.860 0.9931 
 Aza 4.623nM 4.312 to 4.956 0.9977 
 Combination 4.331nM 3.979 to 4.714 0.9961 
H838 Mock 8.075nM 6.887 to 9.467 0.9938 
 Entinostat 7.581nM 6.844 to 8.397 0.9989 
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 Aza 6.797nM 6.175 to 7.481 0.9972 
 Combination 6.492nM 5.303 to 7.947 0.9847 
A549 Mock 6.402nM 5.539 to 7.399 0.9929 
 Entinostat 6.414nM 5.668 to 7.258 0.9938 
 Aza 6.377nM 5.063 to 8.033 0.9780 
 Combination 6.621nM 5.403 to 8.115 0.9871 
Cisplatin 
H1299 Mock 1.777μM 1.400 to 2.256 0.9714 
 Entinostat 1.717μM 1.209 to 2.437 0.9637 
 Aza 1.398μM 1.104 to 1.771 0.9801 
 Combination 1.526μM 0.926 to 2.511 0.9401 
H358 Mock ND - - 
 Entinostat ND - - 
 Aza ND - - 
 Combination ND - - 
H838 Mock ND - - 
 Entinostat ND - - 
 Aza ND - - 
 Combination ND - - 
A549 Mock 2.981uM 2.338 to 3.800 0.9720 
 Entinostat 3.352uM 1.834 to 6.127 0.9620 
 Aza 3.599uM 1.641 to 7.891 0.8781 
 Combination 4.211uM 0.916 to 19.36 0.9108 
Docetaxel 
H1299 Mock 2.345nM 1.903 to 2.889 0.9855 
 Entinostat 2.301nM 1.906 to 2.778 0.9856 
 Aza 2.162nM 1.809 to 2.585 0.9894 
 Combination 2.397nM 2.111 to 2.722 0.9923 
H838 Mock 1.380nM 1.153 to 1.651 0.9862 
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 Entinostat 1.115nM 1.006 to 1.236 0.9949 
 Aza 1.259nM 1.099 to 1.441 0.9920 
 Combination 1.074nM 0.773 to 1.491 0.9615 
A549 Mock 1.121nM 0.742 to 1.693 0.9701 
 Entinostat 0.986nM 0.739 to 1.315 0.9816 
 Aza 1.499nM 1.086 to 2.069 0.9811 
 Combination 1.076nM 0.686 to 1.686 0.9673 
Gemcitabine 
H1299 Mock 7.736nM 6.695 to 8.938 0.9887 
 Entinostat 6.939nM 5.892 to 8.173 0.9888 
 Aza 5.876nM 4.375 to 7.870 0.9656 
 Combination 6.075nM 5.024 to 7.344 0.9854 
H838 Mock 38.55nM 26.08 to 56.98 0.9265 
 Entinostat 42.75nM 31.31 to 58.38 0.9576 
 Aza 38.94nM 27.84 to 54.45 0.9457 
 Combination 44.80nM 31.63 to 63.45 0.9511 
Vinorelbine 
H1299 Mock 2.841nM 2.547 to 3.168 0.9942 
 Entinostat 2.782nM 2.482 to 3.118 0.9944 
 Aza 2.727nM 2.398 to 3.100 0.9934 
 Combination 2.386nM 2.066 to 2.755 0.9901 
H358 Mock 2.844nM 2.274 to 3.557 0.9854 
 Entinostat 2.351nM 1.873 to 2.952 0.9867 
 Aza 2.029nM 1.537 to 2.679 0.9739 
 Combination 2.075nM 1.550 to 2.778 0.9719 
H838 Mock 2.479nM 2.207 to 2.784 0.9899 
 Entinostat 2.422nM 2.143 to 2.738 0.9901 
 Aza 2.172nM 1.928 to 2.446 0.9916 
 Combination 2.034nM 1.732 to 2.387 0.9865 
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A549 Mock 0.736nM 0.640 to 0.845 0.9890 
 Entinostat 0.730nM 0.641 to 0.832 0.9904 
 Aza 0.866nM 0.368 to 2.037 0.9810 
 Combination 0.751nM 0.6210to 0.909 0.9794 
 
Transformed data were then normalized to untreated controls within each 
pretreatment group for a given chemotherapy. Log dose response curves generated from 
normalized data demonstrate minimal differences in response to chemotherapy across cell 
lines, pretreatment conditions, and chemotherapy tested (Figure 13). 
 
Figure 13.  Epigenetic priming does not alter chemosensitivity of NSCLC cell lines. Log dose 
response curves for NSCLC cell lines treated with chemotherapy for 72h one week after 
treatment with epigenetic therapy (50nM entinostat for 24h, 500nM Aza for 72h, combination, or 
mock). Individual curves represent the percentage of viable cells (+/- standard deviation) for each 
epigenetic pretreatment condition normalized to its own untreated control cells, such that the 









































































































































































































































































































































































































































































































































































































   
2.2 Epigenetic therapy does not augment inhibition of colony growth by subsequent 
chemotherapy in NSCLC cell lines 
To further test whether epigenetic therapy sensitizes NSCLC to the effects of 
chemotherapy in vitro, we selected sub- or near-IC50 doses of select chemotherapeutic 
agents and assessed the effects of these agents on colony growth with or without 
pretreatment with epigenetic therapy, using the treatment paradigm previously described. 
H358 and A549 cell lines were initially selected for their ability to form distinct colonies 
on a reconstituted basement membrane matrix. Pretreated cells were seeded on 
Matrigel
TM
 one day prior to 72h treatment with chemotherapy. Colonies were grown an 
additional 2-4 days after treatment, imaged (Figure 14A), and quantified. After 
normalization to untreated controls within each epigenetic pretreatment group, we found 
that prior epigenetic treatment did not alter inhibition of H358 colonies by gemcitabine, 
or 17-AAG (Figure 14B). For A549 cells, pretreatment with azacitidine slightly reduced 
efficacy of 600nM cisplatin (p<0.05), while combination pretreatment resulted a minor 
attenuation of colony inhibition by 1nM docetaxel (p<0.01) (Figure 14C and D). No 
significant differences were noted among pretreatment groups in response to 6nM 




Figure 14.  Epigenetic therapy does not enhance the effects of chemotherapy on colony 
growth on Matrigel
TM
. H358 and A549 cells were seeded on a solidified Matrigel
TM
 layer six 
days after 72h treatment with epigenetic therapy. Beginning the following day, cells were treated 
with chemotherapy for 72h. Drug was then removed and colonies were permitted to grow 2-4 
additional days until stained with MTT reagent and counted. Colony number was then normalized 
to untreated controls (PBS or DMSO) for each epigenetic pretreatment condition. A. 
Representative H358 colonies following treatment with 10nM gemcitabine, 10nM 17-AAG, or 
20nM 17-AAG. B. H358 percent colony formation relative to untreated control calculated from 
one experiment  with 5 replicates. C. Representative A549 colonies following treatment with 
6nM bortezomib, 10nM 17-AAG, 30nM 17-AAG, 600nM cisplatin, or 1nM docetaxel. D. A549 
percent colony formation relative to untreated control, averaged from two independent 
experiments (total 9 replicates). Statistical significance by ANOVA with Tukey’s multiple 


















































































































































We also questioned whether prior epigenetic therapy would affect anchorage 
independent colony growth, a measure of clonogenic potential, of NSCLC following 
treatment with chemotherapy. Prior work has shown that relatively low, non-toxic doses 
of demethylating agents (DAC and Aza) alone can blunt clonogenic and tumorigenic 
potential of leukemia and breast cancer, suggesting depletion of progenitor or tumor 
initiating cell populations [86]. We hypothesized that pretreatment with epigenetic agents 
would also attenuate clonogenic capacity of NSCLC. In addition, if epigenetic 
pretreatment sensitizes NSCLC to chemotherapeutics, we would predict a greater 
attenuation of clonogenic capacity following chemotherapy than achieved with epigenetic 
therapy alone. To test this, we utilized a methylcellulose colony formation assay. H1299 
cells were treated with combination epigenetic therapy or mock as described above. 
Pretreated cells were then treated with 300nM or 600nM cisplatin, or 3nM bortezomib for 
72h, beginning on day 10. At the end of chemotherapy treatment, cells were seeded in 
methylcellulose (10
3
 viable cells per dish in triplicate) and allowed to grow colonies for 
two weeks prior to counting colony number. Pretreatment with the combination of Aza 
and entinostat attenuated colony growth across all chemotherapy doses tested, relative to 
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mock pretreatment (Figure 15A), with the exception of 600nM cisplatin, which abrogated 
colony formation entirely. However, when normalized to untreated control (0nM PBS or 
0nM DMSO) within a given pretreatment group, there were no significant differences in 
colony inhibition resulting from treatment with 300nM cisplatin or 3nM bortezomib 
(p>0.05) (Figure 15B).       
 
Figure 15.  Methylcellulose colony formation following chemotherapy is not altered by 
epigenetic priming. H1299 cells were treated 72h with combination epigenetic therapy, rested 
seven days in drug free media, then treated for 72h with 300nM cisplatin, 3nM bortezomib. 
Following chemotherapy treatment, 10
3
 viable cells were seeded in methylcellulose (in triplicate), 
allowed to grow as colonies for two weeks prior, and counted. A. Percent colony formation of 
combination pretreatment relative to mock pretreatment (+/- standard deviation). B. Percent 
colony formation relative to untreated control within each pretreatment condition (+/- standard 
deviation). p-value determined by unpaired t test. 
H1299























































































































































2.3. in vitro combinatorial epigenetic therapy exerts differential effects on in vivo 
chemosensitivity of NSCLC cell line xenografts 
 Given the limitations of in vitro model systems, we aimed to determine whether in 
vitro pretreatment with the combination of azacitidine and entinostat, following our 
treatment paradigm previously described, alters sensitivity of NSCLC cell line xenografts 
to subsequent chemotherapy in vivo. This model allows for controlled exposure to 
epigenetic therapy prior to establishment of xenografts. Two cell lines, A549 and H460, 
were selected for these studies since their tumor growth rate in vivo is unaffected (A549) 
or only moderately impaired (H460) by epigenetic treatment in vivo. After pretreatment 
and a seven day, drug-free recovery period, cells were injected on day 10 into the flank of 
NOD/SCID mice to establish tumors. 
Tumors established from mock and combination epigenetic pretreated A549 cells 
were allowed to reach approximately 250mm
3
 (+/- 20%) prior to randomization on day 1 
to one of three chemotherapy treatment arms: vehicle (saline) twice weekly, 2mg/kg 
cisplatin weekly, or 10mg/kg irinotecan twice weekly. Chemotherapy treatment was 
initiated on day 2 and lasted for three weeks. All drugs were administered 
intraperitoneally. We observed no difference in growth between mock and combination 
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pretreated tumors that received vehicle or cisplatin (Figure 16A). However, epigenetic 
pretreatment appeared to selectively augment response to irinotecan compared to mock 
pretreatment (Figure 16B). Using a linear mixed effects model, we determined that 
irinotecan treatment decreased the rate of growth of mock pretreated and epigenetic 




/day, respectively, compared to vehicle 
treatment, and that this difference was statistically significant (p=0.00013  by restricted 
maximum likelihood estimation). Therefore, in vitro pretreatment with combination 
epigenetic therapy sensitizes A549 xenografts to irinotecan treatment in vivo. 
 
Figure 16.  Response of A549 xenografts to irinotecan, but not cisplatin, is augmented by 
epigenetic therapy. Subcutaneous hind flank tumors were established in NOD/SCID mice from 
A549 cells treated in vitro with mock or the combination of Aza and entinostat. Once tumors 
reached approximately 250mm
3
, they were randomized to receive 2mg/kg cisplatin (days 2,9,16), 
10mg/kg  irinotecan (days 2,5,9,12,16,19), or saline vehicle (days 2,5,9,12,16,19), all by 
intraperitoneal administration. A. Mean tumor volume (+/- SEM) of mock and combination 
epigenetic pretreated tumors that received vehicle or cisplatin. Pretreatment with epigenetic 
therapy did not alter response to cisplatin. B. Mean tumor volume (+/- SEM) of mock and 
combination epigenetic pretreated tumors that received vehicle or irinotecan. Using a mixed-
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Similar to A549, H460 tumors established from mock and combination epigenetic 
pretreated cells were allowed to reach approximately 250mm
3
 (+/- 20%) and then 
randomized to one of three chemotherapy treatment arms: vehicle (saline), 2.5mg/kg 
docetaxel escalated to 5mg/kg docetaxel, or 10mg/kg irinotecan. Each treatment 
consisted of four intraperitoneal injections beginning on day 1 immediately after 
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randomization. Docetaxel was escalated to 5mg/kg for the final two injections. 
Epigenetic pretreated tumors exhibited a modestly increased rate of growth compared to 
vehicle control in response to docetaxel, while mock pretreated tumors were unaffected 
by docetaxel treatment (Figure 17A). Once tumors volumes for each pretreatment were 
normalized to the corresponding vehicle controls (Figure 17B), we found that the 
differences in response to docetaxel were not significant (p>0.05 by 2-way ANOVA). 
Mock pretreated tumors were modestly inhibited by irinotecan (approximately 40% by 
end of study, compared to vehicle control), while combination epigenetic pretreated 
tumors did not respond to irinotecan treatment (Figure 17C). Comparison of normalized 
tumor volumes revealed a significant difference (p<0.05 by 2-way ANOVA) in response 
to irinotecan between pretreatment groups (Figure 17D).  
 
Figure 17.  Epigenetic therapy desensitizes H460 xenografts to subsequent chemotherapy. 
Hind flank tumors were established in NOD/SCID mice from H460 cells treated in vitro with 
mock or the combination epigenetic therapy. Tumors of approximately 250mm
3
 were randomized 
to receive 2.5mg/kg docetaxel (ip, q4d x 2) escalated to 5mg/kg docetaxel (q4d x 2), 10mg/kg 
irinotecan (ip, q4d x 4), or saline vehicle (ip, q4d x 4). A. Mean tumor volume (+/- SEM) of 
mock and combination epigenetic pretreated tumors that received vehicle or docetaxel. Epigenetic 
pretreatment let to a modest increase in growth in response to docetaxel. B. Response to 
docetaxel for each pretreatment group normalized to its own vehicle control across measurements 
days. Error bars represent 95% CI. Differences in response to docetaxel between pretreatment 
groups were not significant by two-way ANOVA (p>0.05). C. Mean tumor volume (+/- SEM) of 
mock and combination epigenetic pretreated tumors that received vehicle or irinotecan. 
Combination epigenetic pretreatment attenuated response to irinotecan treatment. D. Normalized 
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response to irinotecan (relative to vehicle control) for each pretreatment. Error bars represent 95% 
CI. Significance determined by two-way ANOVA. 
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2.4 in vivo combinatorial epigenetic therapy does not sensitize H358 xenografts to 
cisplatin or irinotecan 
We next assessed whether in vivo epigenetic therapy sensitizes NSCLC tumors to 
immediate subsequent chemotherapy. H358 xenografts were selected due to the slower 
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rate of tumor growth in vivo, permitting for repeated cycles of epigenetic therapy prior to 
chemotherapy. Tumor bearing, nu/nu mice were treated each week with 0.5mg/kg Aza 
subcutaneously on days 1-5 and 1mg/kg entinostat intraperitoneally on day 5, or vehicle, 
for four one-week cycles, and then randomized to chemotherapy arms at the beginning of 
week five (day 29). A similar schedule and dose of entinostat has been used successfully 
in orthotopic models of NSCLC in rats [109]. The dose of Aza was chosen since it is well 
tolerated based on prior laboratory work, and has been shown to be more efficacious in 
certain breast cancer xenografts than higher doses [86]. Following epigenetic therapy, 
mice were treated by with either saline vehicle twice weekly, 2mg/kg cisplatin weekly, or 
10mg/kg irinotecan twice weekly, for four weeks beginning the day after randomization. 
Drugs were administered by intraperitoneal injection. Figure 18A shows that epigenetic 
therapy has a modest effect on tumor growth, and growth inhibition reached significance 
by day 29 (p<0.05 by two-way ANOVA with Bonferroni posttests). H358 xenografts did 
not respond to subsequent cisplatin or irinotecan treatment, regardless of pretreatment 
(Figure 18B).  
 
Figure 18.  Epigenetic therapy in vivo does not sensitize H358 xenografts to immediate 
subsequent chemotherapy. A. Nude mice bearing H358 xenografts were treated with 0.5mgkg 
Aza (sc, days 1-5) and 1mg/kg entinostat (ip, day 5), or vehicle, for four one-week cycles. 
Epigenetic therapy causes a modest tumor growth inhibition that reached significance by day 29 
(p<0.05 by two-way ANOVA with Bonferroni posttests). B. Pretreated mice were randomized to 
one of three chemotherapy arms on day 29: vehicle (ip saline, days 2 & 5), 2mg/kg cisplatin (ip, 
day 2), or 10mg/kg irinotecan (ip, days 2 & 5,). Mice were treated for four one-week cycles. No 
responses to chemotherapy were observed for either pretreatment. Upper Vehicle pretreated 
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mice: Vehicle n=8, Cisplatin n=7, Irinotecan n=6. Lower Epigenetic pretreated mice: Vehicle 
n=6, Cisplatin n=7, Irinotecan n=7.  
H358






































































































2.5 Combination epigenetic therapy has utility as a priming therapy in a patient-derived 
NSCLC xenograft model  
 We extended our study of epigenetic priming to two of our patient-derived 
NSCLC xenograft (PDX) models, LX7 (adenocarcinoma) and LX14 (squamous cell 
carcinoma). These xenografts were previously established in immunocompromised mice 
immediately following collection of cells from NSCLC patients, and serially passaged 
such that they have never been cultured in medium. Similarly derived small cell lung 
cancer PDXs have previously been shown to exhibit gene expression patterns more 
closely related to primary patient tumors than to cell lines derived from the PDXs [133]. 
Therefore, we believe our NSCLC PDXs may better represent patient tumors than 
standard cell line xenograft models. 
 To assess the effects of epigenetic priming on response of LX14 to subsequent 
gemcitabine therapy, tumors were established in NOD/SCID mice from LX14 cell 
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suspensions harvested from freshly grown tumors. Treatment began when tumors reached 
approximately 115mm
3
 (+/- 30%). Mice received epigenetic therapy (n=7) or vehicle 
(n=7) for three weeks as follows: 0.5mg/kg Aza (or vehicle) subcutaneously on days 1-5 
and 1mg/kg entinostat (or vehicle) intraperitoneally on day 5. Epigenetic therapy resulted 
in minor, but not statistically significant (p=0.14 by two-way ANOVA), tumor growth 
inhibition (Figure 19A). All mice within the vehicle treatment arm were euthanized and 
tumors harvested on day 20, while mice in the epigenetic arm remained on study until 
day 22. Representative tumors from the vehicle arm were pooled and mechanically 
disrupted to form a single cell suspension. All tumors from the epigenetic treatment arm 
were pooled due to the larger variation in tumor size at the time of harvest. Viable cells 





cells/mouse). Mice bearing tumors that reached 
approximately 250mm
3
 (+/- 20%) were randomized to receive 30mg/kg gemcitabine or 
vehicle every third day for five intraperitoneal injections. LX14 tumors were highly 
sensitive to gemcitabine, remaining relatively cytostatic for the duration of treatment. 
Epigenetic therapy did not improve duration of response, as tumors rapidly increased in 
size upon cessation of gemcitabine treatment, comparable to vehicle pretreated tumors 
(Figure 19B).  
  
Figure 19.  Epigenetic therapy does not extend duration response to gemcitabine in a 
patient derived xenograft model of squamous cell carcinoma. A. LX14 bearing NOD/SCID 
mice received sc Aza on days 1-5 and ip entinostat on day 5, or vehicle, weekly for three weeks 
(n=7 per arm). Differences in tumor growth between vehicle and epigenetic arms were not 
significant by two-way ANOVA with Bonferroni posttests. B. NOD/SCID mice bearing LX14 
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tumors established from pooled vehicle or epigenetic pretreated tumors were treated with 
30mg/kg gemcitabine (ip, q3d x5) or vehicle. Both pretreatment arms responded strongly to 
gemcitabine, and prior epigenetic therapy did not delay rapid growth of tumors following 
cessation of gemcitabine treatment. 
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We employed a similar study design with our second PDX model, LX7.  Once 
tumors reached approximately 160mm
3 
(+/- 25%), LX7 bearing NOD/SCID mice were 
randomized to receive vehicle (n=9) or epigenetic therapy (n=9), with the same doses and 
route of administration as used for LX14. Mice were treated with Aza on days 1-3, 6-10, 
13-17, and entinostat on days 3, 10, 17. Combination epigenetic therapy resulted in a 
modest, but statistically significant (p=0.0055 by linear mixed effects model and 
restricted maximum likelihood estimation) inhibition of LX7 growth (Figure 20A). 
Representative tumors from the vehicle and epigenetic arms were harvested days 16 and 
17, respectively. Tumors within a given treatment arm were pooled, mechanically 
processed into a single cell suspension, and frozen for later use. Pretreated cells were 
later thawed, counted, and injected into the hind flank NOD/SCID mice (1.3x10
6
 viable 
cells/mouse) to establish subcutaneous tumors for treatment with chemotherapy. Mice 
bearing tumors of approximately 140mm
3 
(+/- 15%) were randomized to receive 2mg/kg 
cisplatin weekly, 10mg/kg irinotecan every fourth day, or vehicle every fourth day. 
Treatment consisted of two cisplatin, three vehicle, or three irinotecan intraperitoneal 
injections. No significant difference in response to cisplatin or irinotecan was observed 
between vehicle and epigenetic pretreated tumors, with minimal response to cisplatin and 
slight tumor regression in response to irinotecan for both pretreatment conditions (Figure 
20B). However, the growth rate of irinotecan treated tumors in both pretreatment arms 
increased within three days of cessation of irinotecan treatment. Vehicle and cisplatin 
treated mice were euthanized on day 22 due to large tumor burden, while irinotecan 
treated tumors were allowed to grow. By day 32, we noted a small difference in mean 
tumor volume (+/- SEM) between pretreatment arms (1345 ± 136 mm
3
 for vehicle 
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pretreated vs. 1072 ± 131 for epigenetic pretreated), however this difference was not 
significant (p=0.19 by t test). Beginning on day 32, mice were subjected to a repeat cycle 
of irinotecan therapy (10mg/kg days 32, 36, 40) to determine whether response to 
irinotecan following tumor regrowth was altered by prior epigenetic therapy. Two of 
eight mice within the vehicle pretreatment arm were euthanized early due to excessive 
body weight loss (day 42, final tumor volume = 1576mm
3
) and a large ulcerated tumor 
(day 45, final tumor volume = 2789mm
3
). Interestingly, epigenetic pretreated LX7 
tumors exhibited increased sensitivity to irinotecan upon repeat exposure, with regression 
of mean tumor volume to slightly below baseline (day 32), compared to vehicle 
pretreated tumors, exhibited only a brief, mean cytostatic response (Figure 20C and D). 
Using a linear mixed effects model, and adjusting for the difference in tumors sizes 
between arms at the initiation of repeat treatment on day 32, we determined that mean 
tumor volume increases 33.5mm
3
/day in vehicle-pretreated mice, whereas in epigenetic 
pretreated mice, volume increases by 23.9mm
3
/day (p=0.013 by restricted maximum 
likelihood estimation). In both arms, tumor growth rapidly increased roughly one week 
after the final dose of irinotecan, indicating that the degree of response, but not duration, 
was altered by epigenetic priming. 
 
Figure 20.  Epigenetic therapy sensitizes a patient derived model of adenocarcinoma to 
repeat treatment with irinotecan, but does not sensitize to cisplatin. A. LX7 bearing 
NOD/SCID mice were treated with 0.5mg/kg Aza (sc) on days 1-3, 6-10, 13-17, and 1mg/kg (ip) 
entinostat on days 3, 10, 17, or vehicle (n=9 per arm). Epigenetic therapy inhibited LX7 tumor 
growth by approximately 23% by day 15. Significance determined using a linear mixed effects 
model and restricted maximum likelihood estimation. B. NOD/SCID mice bearing LX7 tumors 
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established from pooled vehicle or epigenetic pretreated tumors were treated with 10mg/kg 
irinotecan (ip, q4d x 3), 2mg/kg cisplatin (ip, q7d x 2), or vehicle. Both pretreatment arms 
responded strongly to irinotecan, but exhibited minimal response to cisplatin. C-D. Irinotecan 
tumors were allowed to grow following cessation of treatment. On day 32, mice were re-
challenged with 10mg/kg irinotecan on days 32, 36, and 40 (same dose and schedule as first 
cycle). Epigenetic pretreated LX7 tumors exhibited greater response to repeat irinotecan therapy 
(p=0.013 by linear mixed effects model and restricted maximum likelihood estimation). *Two 
mice in the Vehicle – Irinotecan arm were euthanized early (day 42 and 45 after final 
measurements) for n=6 after day 45. 
LX7
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 Our in vitro assays generally showed no evidence in support of the epigenetic 
priming hypothesis. It is plausible that an important component necessary for effective 
epigenetic priming in NSCLC is interaction of epigenetic pretreated cells with the host 
tumor microenvironment, something that is absent in these models. In our results from 
the Matrigel
TM
 colony formation assays, pretreatment of A549 with Aza and combination 
appears to slightly attenuate the effects of cisplatin and docetaxel, respectively. These 
results suggest that the effects of epigenetic pretreatment of NSCLC on response to 
subsequent chemotherapy may vary with a given epigenetic or chemotherapeutic agent. 
However, it is important to note that, while statistically significant, the differences are 
minor. In addition, these negative effects were not observed in our cell viability 
experiments, or in the more relevant xenograft model. Response of A549 xenografts to 
cisplatin therapy following in vitro pretreatment with combination epigenetic therapy was 
unaltered. Response of H358 and LX7 xenografts to cisplatin therapy was also 
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unchanged. We did, however, note that epigenetic priming had a negative impact on 
response of H460 xenografts to irinotecan, and resulted in a slightly increased rate of 
growth of docetaxel treated tumors compared to vehicle treated.  
These results are contrary to the sensitization observed in A549 and LX7 
xenografts. Xenografts established from mock pretreated A549 cells were minimally 
responsive to irinotecan, whereas tumors grown from epigenetic pretreated cells 
exhibited increased sensitivity to the same irinotecan therapy. The data are striking given 
that transient (72h) in vitro treatment with epigenetic therapy did not affect the growth of 
A549 xenografts, yet altered the response of established xenografts to a chemotherapeutic 
agent weeks later. This is of interest in light of the clinical observations of several 
patients whose disease progressed on epigenetic therapy but who experienced better than 
expected responses to subsequent chemotherapy. Both our data and the clinical trial 
observations suggest that the effects of epigenetic therapy, even if not sufficient to 
provide an anti-tumor response, can be durable, and that immediate response may not be 
necessary for patients to derive benefit from this approach.  LX7 PDXs established from 
vehicle and epigenetic pretreated LX7 tumors both responded strongly to initial, short 
duration (three injections) irinotecan therapy, but recovered relatively quickly following 
cessation of treatment. Upon treatment with a second regimen of irinotecan, epigenetic 
pretreated LX7 tumors exhibited increased response to therapy, characterized by a slowed 
growth rate followed by regression of mean tumor volume to slightly below baseline (day 
32). In comparison, vehicle pretreated tumors exhibited an increased rate of growth, 
followed by a very brief period of cytostatic behavior, but not tumor regression. The LX7 
data are particularly intriguing for two reasons. First, LX7 is a patient-derived 
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adenocarcinoma model maintained in mice and may better reflect the biology of disease 
than ex vivo cell line models, as suggested by earlier data from our group [133]. Second, 
LX7 tumors responded well to initial therapy, but grew quickly after treatment ended, 
which is reminiscent of the short-lived response to chemotherapy seen in many NSCLC 
patients. In addition, tumors that had no prior exposure to epigenetic therapy did not 
respond as well to the second cycle of irinotecan therapy, which is often the case for 
recurrent NSCLC, while tumors previously exposed to epigenetic therapy again exhibited 
a small degree of tumor regression prior to regrowth roughly one week after the end of 
irinotecan therapy. Since H460 comprises a different histology than A549 and LX7 (large 
cell carcinoma vs. adenocarcinoma, respectively), it is possible that the utility of 
epigenetic priming may vary with disease. 
Using two models of human lung adenocarcinoma, the cell line, A549, and the 
patient-derived primary xenograft, LX7, we demonstrated sensitization of established 
xenografts to irinotecan chemotherapy following prior exposure to combinatorial 
epigenetic therapy in vitro and in vivo, respectively. These data suggest the potential for 
epigenetic therapy to sensitize NSCLC to a given subsequent chemotherapy, and support 
our clinical observations in which advanced stage, NSCLC patients with a median of 
three prior therapies achieved better than expected responses to subsequent chemotherapy 
following treatment with the combination of azacitidine and entinostat. 
Nonetheless, it must be acknowledged that in the majority of models and with the 
majority of cytotoxic chemotherapy agents tested, we were not able to demonstrate that 
combinatorial epigenetic therapy with azacitidine and entinostat enhanced tumor 
sensitivity to subsequent chemotherapy. Taken together, these data call into question 
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whether in fact azacitidine and entinostat exposure could augment chemotherapeutic 
efficacy in a substantial fraction of lung cancer patients. There are many potentially 
relevant differences between efficacy in preclinical models and clinical outcome in 
patients, notably differences in drug pharmacokinetics. A randomized phase II clinical 
trial to specifically address this question in patients with advanced lung cancer has been 
initiated at Johns Hopkins, with plans to expand this study to a number of other 
collaborating centers. This study offers the opportunity to address this hypothesis 
directly. Comparative data from the clinical trial in progress and the preclinical work 
presented here will be of interest in defining the extent to which these preclinical models 
can reflect treatment paradigms of relevance to the human disease. 
 
4. Materials and Methods 
Cell lines and Reagents 
NCI-H1299, NCI-H358, NCI-H838, NCI-H460, and A549 were obtained from the 
American Type Culture Collection (ATCC) and cultured in RPMI-1640 supplemented 
with 10% FBS, penicillin/streptomycin, 2 mmol/L l-glutamine, 1 mmol/L sodium 
pyruvate, 10 mmol/L HEPES buffer, and 1.5 g/L sodium bicarbonate. Cells were cultured 
in a humidified incubator at 37ºC with 5% CO2. 
 
Drugs and Reagents 
5-azacitidine (Aza) was purchased from Tocris Bioscience. For in vitro use, Aza was 
dissolved in 1x PBS as a 4mM stock and stored at -80ºC in aliquots. Fresh aliquots of 
Aza were thawed immediately prior to use. For in vivo studies, Aza was dissolved in 
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saline (0.9% sodium chloride) at 1mg/mL and stored at -80ºC in aliquots. Fresh aliquots 
were thawed and diluted 1:10 in saline immediately prior to injection. Entinostat was 
provided by Syndax Pharmaceuticals. For in vitro experiments, entinostat was dissolved 
in DMSO as a 200uM solution stored at -20ºC. Drug was thawed immediately prior to 
use and diluted 1:4000 in culture medium to provide a final concentration of 50nM 
entinostat and 0.025% DMSO in medium. For in vivo use, entinostat was dissolved at 
2mg/ml in DMSO and stored at -20ºC. Immediately prior to injection, entinostat was 
thawed and diluted 1:10 in saline for a final of 10% DMSO per injection. 17-AAG and 
bortezomib were purchased from LC Labs. Docetaxel and vinorelbine were obtained 
from Selleck Chemicals. Each was dissolved in DMSO, and appropriate dilutions in 
DMSO were made for in vitro studies to provide a final of 0.025% DMSO in medium. 
Cisplatin (APP Pharmaceuticals) and Gemcitabine (Sagent Pharmaceuticals) were 
obtained from the Johns Hopkins Hospital pharmacy. Gemcitabine was dissolved in 
saline. For in vitro use, cisplatin and gemcitabine were diluted with 1x PBS. For in vivo 
experiments, both drugs were diluted in saline. Docetaxel (Hospira) and Camptosar 
(Pfizer) were obtained from the Johns Hopkins Hospital pharmacy for in vivo use, and 
were diluted in saline prior to injection.  
 
Treatment of cell lines with epigenetic therapy 
H1299, H358, H838, A549, and H460 cells were seeded at 2 x 10
5











 culture flask, respectively, and allowed to adhere 
approximately 20-24h. Cells were then treated with 500nM Aza or mock (1x PBS) in 
fresh media every 24h for 48h, then treated with 500nM Aza, 50nM entinostat, 
107 
 
combination, or mock (1x PBS) for the final 24h of treatment. All treatments contained a 
final of 0.025% DMSO for the final 24h treatment. After 72h of treatment, cells were 
harvested and re-seeded at equal density for all treatment conditions in drug-free media.  
 
Cell viability assays 
Following epigenetic treatment, cells were cultured for six days in drug free media. On 
day 9, cells were seeded in triplicate in opaque walled 96-well plates as follows: H1299 = 
1000 cells/well, H358 = 4200 cells/well, H838 = 1700 cells/well, A549 = 1500 cells/well. 
Approximately 24h later, cells were treated with 17-AAG (3-1000nM, 0.03-10uM for 
H358), bortezomib (1-300nM), cisplatin (0.03-10uM), docetaxel (0.3-100nM, 0.3-30nM 
for A549), gemcitabine (1-300nM), or vinorelbine (0.3-100nM) for 72h. Following 
chemotherapy, ATP content was measured as an indicator of cell viability using the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega). Cells were incubated with 
prepared CellTiter-Glo reagent for 10 min at room temperature, and luminescence was 
read on a SpectraMax M2e plate reader (Molecular Devices). Raw data were corrected 
for background luminescence, transformed (x=log(x)), and analyzed by nonlinear 
regression using the equation, log(inhibitor) vs. response with variable slope in GraphPad 
Prism 5 to obtain IC50 values, 95% confidence intervals, and R
2
. IC50 was considered 
not determined if the value calculated by Prism was ambiguous. Transformed data were 
then normalized to untreated controls within each pretreatment group for a given 
chemotherapy to generate log dose response curves. Experiments were repeated at least 
twice to ensure consistent results, with the exception of vinorelbine for H358 and H1299, 






 Colony formation assays 
Following epigenetic treatment, cells were cultured for six days in drug free media. On 
day 9, cells were seeded 96-well plates on a 40uL layer of solidified Matrigel
TM
, with 4-5 
replicates per pretreatment condition, as follows: H358 = 2000 cells/well, A549 = 1000 
cells/well. Approximately 24h later, H358 cell were treated with 10nM gemcitabine, 
10nM 17-AAG, or 20nM 17-AAG. A549 cells were treated with 600nM cisplatin, 6nM 
bortezmib, 10nM 17-AAG, 30nM 17-AACG, or 1nM docetaxel. After 72h, 
chemotherapy was removed, cells were rinsed once with 1x PBS, and drug free media 
was added. Colonies were grown an additional 2-4 days, stained with MTT reagent, and 
imaged and counted on the GelCount
TM
 colony counter (Oxord Optronix). Colony 
number was normalized to untreated control within a given pretreatment group to 
determine % colony formation after chemotherapy. 
 
Methylcellulose colony formation assay 
Following epigenetic treatment, mock and combination pretreated H1299 cells were 
cultured for seven days in drug free media. On day 10, cells were treated for 72h with 
300nM cisplatin, 600nM cisplatin, or 3nM bortezomib. Cells were then harvested, counted, and 
seeded in Methocult
TM
 methylcellulose medium at 1000 cells per dish, in triplicate. After 
incubation for two weeks, colonies of greater than 30 cells were counted under an inverted 
microscope. Colony number was normalized to untreated control within a given 
pretreatment group to determine % colony formation after chemotherapy. 
 
Animal xenografts studies 
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Protocols for all animal experiments were approved by the John Hopkins University 
Animal Care and Use Committee and were strictly followed. All xenografts were 
established from cells injected subcutaneously into the right hind flank of 5-7 week old 
female mice, in a total volume of 100uL, consisting of a 50:50 mix of 1x PBS and 
Matrigel
TM
. Tumor volume measurements were calculated as (L x W
2
)/2. Aza was 
administered subcutaneously at 0.5mg/kg. Entinostat was administered intraperitoneally 
at 1mg/kg. All other chemotherapeutics were administered intraperitoneally. Vehicle for 
entinostat was 90% saline/10% DMSO. All other vehicle injections were saline. Injection 
volume was 5mL/kg for all drugs. 
  
Xenografts established from pretreated cells 
Following epigenetic treatment, mock and combination pretreated A549 and H460 cells 
were cultured for seven days in drug free media. On day 10, cells were harvested and 
counted, and 6.5 x 10
5
 (A549) and 2.75 x 10
5
 (H460) cells were injected into NOD/SCID. 
Tumors were grown to a starting size of 250mm
3
 (+/- 20%), then added to study. A549 
bearing mice were treated with 2mg/kg cisplatin (days 2,9,16), 10mg/kg irinotecan (days 
2,5,9,12,16,19), or vehicle (days 2,5,9,12,16,19). H460 bearing mice were treated with 
2.5mg/kg docetaxel (q4d x 2) escalated to 5mg/kg docetaxel (q4d x 2), 10mg/kg 
irinotecan (q4d x 4) or vehicle, starting on day 1.  
 
H358 xenografts and therapeutic administration of epigenetic therapy 
Treatment naïve H358 cells were injected nu/nu mice (8 x 10
5
 cells/mouse) and tumors 
were grown to a starting size of 110mm
3
 (+/- 25%). Mice were treated each week with 
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0.5mg/kg Aza (days 1-5) and 1mg/kg entinostat (day 5), or vehicle, for four one-week 
cycles. Beginning week five, mice received 2mg/kg cisplatin (day 2), 10mg/kg irinotecan 
(days 2 & 5), or vehicle (days 2 & 5), weekly for four weeks.  
 
Patient-derived primary xenografts experiments 
Treatment naïve LX14 and LX7 cells collected from freshly grown tumors were injected 
into NOD/SCID mice (10
6
 cells/mouse). LX14 tumors were grown to a starting size of 
115mm
3
 (+/- 30%). Mice were then treated with vehicle or epigenetic therapy consisting 
of Aza (days 1-5) and entinostat (day 5) for three weeks. On day 20, representative 
vehicle tumors were harvested and pooled, single cells suspensions were generated, and 
7.5x10
5 
cells/mouse were immediately injected into new NOD/SCID mice. On day 22, all 
epigenetic tumors were harvested and pooled, single cell suspensions were generated and 
5x10
5 
cells/mouse were immediately injected into new NOD/SCID. Vehicle and 
epigenetic pretreated tumors were allowed to reach approximately 250mm
3
 (+/- 20%) and 
randomized to recieve 30mg/kg gemcitabine or vehicle every third day for five injections. 
LX7 tumors were grown to a starting size of approximately 160mm
3 
(+/- 25%). Mice 
were randomized to receive vehicle or Aza (days 1-3, 6-10, 13-17) and entinostat (days 3, 
10, 17). On day 16 and 17, representative vehicle and epigenetic treated tumors, 
respectively, were harvested and pooled. Single cell suspensions were generated and 
frozen at -80°C in 90% FBS/10% DMSO for later use. Cells were later thawed on the 
same day, and 1.3 x 10
6
 cells/mouse for both pretreatment conditions were injected into 
NOD/SCID mice. Once tumors reached approximately 140mm
3 
(+/- 15%), mice were 
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treated with 2mg/kg cisplatin (days 1,8), 10mg/kg irinotecan (days 1,5,9 and 32,36,40), 
or vehicle (days 1,5,9).  
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IV. Conclusions and Future Directions 
Using a mouse model to assess tumorigenicity of NSCLC cell lines following 
their treatment in vitro with Aza and entinostat, we have demonstrated that epigenetic 
based therapies can produce striking anti-tumor effects in select xenografts independent 
of apparent cytotoxicity in these cell lines in vitro. Growth of H358 and H1299 
xenografts was significantly impaired following Aza treatment in vitro, despite the lesser 
degree of cytotoxicity in short term viability experiments observed in these compared 
several other cell lines. While we observed impaired proliferation with concordant 
increased cell death cell in Aza and combination treated H358 cells for several days 
following treatment, these cells were indistinguishable from control cells by the day of 
tumor cell injection into mice. Furthermore, despite antagonistic effects on cell viability 
in combination matrix assays, and only minor effects on proliferation post treatment, in 
vitro treatment with combination of Aza and entinostat profoundly inhibited growth of 
H1299 xenografts. Conversely, for cell lines exhibiting the highest degree of cytotoxicity 
in short term viability assays, and substantial decreases in cell viability and colony 
formation after treatment, epigenetic therapy exerted only minimal (H2170) to modest 
(H460) effects on tumorigenicity. 
These data clearly indicate that the effects of Aza and entinostat on tumorigenicity 
of NSCLC cell lines do not directly correlate with acute cytotoxicity resulting from 
treatment with these agents. This strongly suggests that the anti-tumor effects we 
observed were due, at least in part, to alteration of the epigenome. Studies using similar 
models of leukemia and breast tumorigenicity have associated Aza-induced epigenomic 
changes with anti-tumor efficacy [86], but we have yet to demonstrate this in our NSCLC 
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models. Similar epigenomic reprogramming following Aza and entinostat treatment in 
vivo has been demonstrated using a rat orthotopic model of NSCLC, however these 
studies did not address the effects of entinostat alone [109]. Therefore, it is important that 
our future work address the epigenomic changes resulting from Aza and entinostat 
treatment in our NSCLC cell line panel.  
To that end, we have sampled cells at the end of treatment, one week, and two 
weeks after treatment, to assess methylation of >485,000 sites using the Illumina 
Infinium HumanMethylation450 BeadChip array and expression of >41,000 genes using 
the Agilent 44K Gene Expression array. While some studies have associated epigenetic 
changes with response to demethylating agents and HDAC inhibitors in the clinic, this 
has been particularly challenging to clearly demonstrate [80, 110, 111, 114]. Therefore, it 
is important that we determine whether subsets of genes can be correlated with response 
in our tumorigenicity models. In addition, we aim to identify changes in protein 
expression in cells collected one week after treatment using iTRAQ technology. These 
studies are limited to assessment of proteins present in whole-cell extract, and therefore 
will omit insoluble membrane proteins, but provide a means of assessing changes in a 
large number of proteins, and may provide critical insight to the relevance of many of the 
transcript changes observed in the gene expression analysis.  
Our data in a small panel of NSCLC cell lines shows that only select xenografts 
are significantly affected by epigenetic therapy, which agrees with the results from the 
phase I/II trial of Aza and entinostat in heavily pretreated patients with advanced stage 
NSCLC where only a small percentage of patients benefited substantially from 
combinatorial epigenetic therapy. It remains to be seen whether this therapy will have 
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greater utility in patients with earlier stage disease who have undergone fewer prior 
therapies. Preclinically, it is important to extend this work to a greater number of cell 
lines to better define an overall response rate in these models, and to more accurately 
associate epigenomic changes with response to therapy. While cell line models certainly 
have limitations with respect to biomarker discovery, these studies may help provide a 
candidate gene signature for assessment as clinical biomarkers predictive of patient 
response. Ongoing preclinical and clinical work to define relevant biomarkers will be 
essential for the proper determination of a target patient population. 
It should also be acknowledged that our data highlight the limitations of using 
standard in vitro cytotoxicity assays to assess sensitivity of cell lines to epigenetic agents. 
The most profound response achieved in our tumorigenicity model occurred in using a 
cell line (H1299) that exhibited little to no evidence of sensitivity to combinatorial 
epigenetic therapy in shorter term in vitro assays. This exemplifies, preclinically, the 
gradual nature and durability of response to epigenetic therapy in patients treated with 
lower, less toxic doses of these agents, and differs substantially from the rapid, but 
generally short-lived responses achieved with conventional cytotoxic therapy 
administered near the MTD. 
In addition to the effects on tumorigenicity, we found that combinatorial 
epigenetic therapy can alter sensitivity of NSCLC both cell line and patient derived 
xenografts to subsequent irinotecan chemotherapy. However, results with other 
chemotherapeutic agents were disappointing, with little to no improvement in 
chemosensitivity noted in our in vitro and in vivo models. Overall, these data suggest that 
the fraction of NSCLC tumors that exhibit altered sensitivity to subsequent chemotherapy 
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may only represent a small fraction of patients. However, we acknowledge that our 
model systems encompassed a limited number of NSCLC lines and chemotherapeutic 
agents. Expansion of this work to cover additional lines and relevant therapies, both 
cytotoxic and targeted (such as EGFR inhibitors, for example) may yield different 
conclusions. In addition, our in vitro dosing of Aza and entinostat was fixed, and may not 
represent the optimal dosing strategies to augment chemotherapeutic efficacy in these 
model systems, and exploration of additional dosing regimens will be important in 
defining the value of epigenetic priming in preclinical models. Ultimately, it is essential 
to specifically address this priming strategy in the clinic, and to that end, a randomized 
phase II clinical trial in patients with advanced lung cancer has been initiated at Johns 
Hopkins to formally test this. 
Still, preclinical studies of epigenetic priming like the work presented here may 
prove valuable. While we observed sensitization of A549 and LX7 xenografts to 
irinotecan following combinatorial epigenetic therapy, we have yet to address the 
mechanisms responsible. Assessment of gene expression changes before and after 
irinotecan therapy may provide inside into the pathways altered by epigenetic therapy 
that may invoke enhanced sensitivity to irinotecan. Identification of candidate genes 
would allow for more specific mechanistic studies involving manipulation of gene 
expression or pathway activation. In addition, it is important that we assess whether A49 
and H460 respond similarly in vitro to the active metabolite of irinotecan, SN38, 
following epigenetic therapy, as this would enable detailed mechanistic studies using our 
existing model systems.  
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While there are key differences between efficacy in our preclinical models and 
clinical outcome in patients, including pharmacokinetics, the tumor microenvironment, 
and the involvement of the patient’s immune system, comparative data from the clinical 
trial in progress and the preclinical work presented here will help define the relevance of 
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